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Abstract

A series of amphipathic peptides rich in a , a-disubstituted amino acids
(aaA A ’s) was synthesized and studied for antimicrobial activity and helix
preferences in various solvent systems. In addition, a constrained lactam dipeptide
amino acid was synthesized and incorporated into a peptide to examine p-sheet dimer
formation.
Several short, amphipathic, 310- and a-helical peptides containing 80%
aotAA’s were synthesized using various combinations of 1-aminocyclohexane-lcarboxylic acid, a-aminoisobutyric acid, and 4-aminopiperidine-4-carboxylic acid.
The peptides showed direct antimicrobial activity against E. coli and S. aureus. In
addition, several of the peptides showed in vivo and in vitro activity against Brucella
abortus and Mycobacterium chelonei. Studies were done with a strain of B. abortus
expressing a green fluorescent protein to show the peptides selectively destroyed
infected macrophages.
The series of amphipathic 3i0- and a-helical peptides were also studied, using
circular dichroism spectroscopy, for their helix preference in organic and aqueousorganic solvent systems. The a-helical peptides showed the expected spectra in all
solvents used. One designed 3 10-helical peptide exhibited a transition from a 3i0-helix
to an a-helix as the water content was increased. The other designed 3i0-helical

Xlll
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peptide exhibited a spectrum indicative o f an a-helix in all solvents tested,
presumably due to steric interactions o f the amino acid side-chains.
A constrained

lactam dipeptide amino acid, 3-(R)-Ar'-[(9H-fluoren-9-

ylmethoxy)carbonyI]-amino-1-[ 1-(S)-methylethylethanoic acid]-2-piperidinone, was
synthesized from D-glutamic acid and incorporated into a peptide.

The starting

material was esterified with allyl alcohol and the a-nitrogen was doubly protected
with Boc protecting groups.

Selective DIBAL reduction o f the side-chain ester

yielded the semi-aldehyde. Reductive amination with valine followed by removal of
the remaining allyl ester and intramolecular amide bond formation yielded the fully
protected constrained lactam dipeptide amino acid.

Treatment with TFA and

introduction of the Fmoc protecting group resulted in the amino acid ready for peptide
coupling. A peptide using the constrained amino acid was synthesized and studied for
[3-sheet dimer formation.

xiv
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Chapter 1
Introduction
1.1 Introduction
The basic component of ail proteins and peptides is the amino acid. There are
approximately twenty encoded and hundreds of post-translationally modified amino
acids in nature that have the general structure shown in Figure 1.1

O
H2N

I

CH— C

I

OH

R

Figure 1.1. General structure of an amino acid.

As can be seen in Figure 1.1, the proteinogenic amino acids, with the exception
of glycine, exist as enantiomers. In nature, the L-amino acid is the most common. The
structures of the side chains of the twenty encoded amino acids are the distinguishing
feature.

The carbon atom bonded to the carbonyl carbon depicted in Figure 1.1 is

designated as a and the atoms of the side chains are commonly designated as p, y, 6, e, £,
in order away from the a carbon.
Amino acids that can be incorporated into proteins and peptides are not limited to
the twenty encoded ones. Synthetic amino acids are routinely included in many protein
and peptide sequences. Side chains that do not occur in biological systems distinguish
synthetic amino acids from their natural counterparts. As a result, many synthetic amino

1
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acids are incorporated into peptides to study their effects on the peptide’s secondary
structure.
1.2 Secondary Structures in Peptides
Amino acids can be chemically bonded to each other to form peptides and proteins.
A peptide is generally considered a short chain of residues with a defined sequence.
There is no maximum number of residues but if the physical properties of the chain are
those expected from the sum of the residues and no fixed three-dimensional
conformation exists, the term peptide is appropriate. The term protein is usually used for
those polypeptides that occur in nature and have definite three-dimensional structure
under physiological conditions.1' 1 This volume of work will focus on peptides.
The backbone of a peptide chain consists of a repeated sequence of three atoms of
each residue in the chain - the amide N, the C“ and the carbonyl C. These atoms are
represented as Ns, C “, and C ,, respectively, where i is the number of the residue starting
from the amino end o f the chain.
Peptides can adopt defined 3-D structures that are primarily stabilized by hydrogen
bonds and secondarily by hydrophobic, electrostatic and steric interactions.

1 l-l 4

Helices and turns depend on intramolecular hydrogen bonds in the peptide chain for
structural stability. {3-sheets form as a result of either inter or intramolecular hydrogen
bonds between peptide segments. Hydrophobic interactions further stabilize the (3-sheet.
Secondary structures that are not included above are classified as random coil. The
random coil has no regular, repeating structure in significant stretches of the peptide
14

chain. '

The (3-sheet results from two or more ^-strands forming interchain hydrogen
2
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1 1-1 4

bonds. Two types o f [3-sheet are known: anti-parallel and parallel. '

The N—>C

sequence of the participating strands occur in the same direction in the parallel [3-sheet.
In the anti-parallel [3-sheet, the N—»C sequence is opposite in the participating strands.
The (3-strands comprising the (3-sheet are almost fully extended with hydrogen bonds
occurring between every other carbonyl oxygen and amide proton in the opposing
strands. The hydrogen bonding patterns of the two types are shown in Figure 1.2.

A / =—o ^
H—N

J

0 = \

y=o

y=o —

'H - N

/= 0 ^

H -N

J

J

J

y

<
>

N -H

N -H -------- 0 = (

c^ =0

y=o
''H -N

H -N

J

J

0=\
,- - 0 = r (
N -H ''
n -H

H -N

y=0

0= (

<

/= o ^

^

H—N

^ 0= (
N -H ''
N- H

c

h —n

------- H—N
V=0

<

0=^

N -H

N -H -------- 0 = ^

S

^=o

= ° — H—N

''H —N

H—N

y

)= 0

y

Parallel

Antiparallel

Figure 1.2. Hydrogen bonding patterns of the beta sheet structures.
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Turns are types of secondary structures that help promote a change in direction of a
1113

peptide chain. '

Incorporation of a turn allows helices and (3-sheets to fold back on

themselves. Turns are distinguished by the number of residues they contain. (3-Tums
have four residues and a hydrogen bond between the carbonyl of the /th residue and the
amide proton of the t* + 3 residue. y-Tums contain three residues and a hydrogen bond
between the /*h and /*" + 2 residues. The types of turns are defined by the conformations
o f the /*** + 1 residue in the y-tum and the i* + 1 and /* + 2 torsional angles in the (3turns.

1.3

The most common secondary structure is the helix.

Helices are stabilized by

hydrogen bonds that are almost parallel to the helix axis. The hydrogen bond acceptors
are the carbonyl oxygens while the hydrogen bond donors are the amide hydrogens. Side
chain interactions, such as salt bridges, hydrophobic interactions and steric constraints,
1 1-1 4

may further stabilize the helix. '

The right-handed helix, promoted by L-ammo

acids, is the most common form of helix found in nature. The left-handed helix is
promoted by D-amino acids and is far less common in nature. The two most common
helices are the a-helix and the 3i0-helix. The a-helix comprises approximately 90% of
all helices found in nature. In this helix type, the amide proton of the /th residue is the
hydrogen bond donor while the carbonyl oxygen of the i* + 4 residue is the hydrogen
bond acceptor. There are 3.6 residues per turn and a pitch of 1.5A per residue. The a helix is also known as a 3.6I3-helix with 3.6 being the number of residues per turn and 13
being the number of atoms between the hydrogen bond donor and acceptor.

4
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1 l-l 4

The 3,0-helix comprises approximately 10% of all helical structures found in
nature.1'5 ,1-6 The amide proton of the /th residue acts as the hydrogen bond donor while
the carbonyl oxygen of the /* + 3 residue acts as the hydrogen bond acceptor. This
hydrogen bonding pattern results in a 10-membered ring. As a result, the 3 )0- helix is
more compact and longer than the a-helix.1'3, 1,6

Figure 1.3 shows the hydrogen

bonding patterns of the a-helix and 3i0-helix.
Determining secondary structure a priori from the amino acid sequence (known as
primary structure) is the ultimate goal of peptide and protein chemistry. Ideally, if one
wishes to design a peptide or protein with a particular secondary structure, we would
only need to include those amino acids known to promote the desired structure.
Unfortunately, this task is not so simple as many factors (i.e., hydrogen bonding,
electrostatic and hydrophobic interactions) affect secondary structure. However, one can
gain much information by studying the conformational restrictions placed on the peptide
backbone.
Figure 1.4 shows the conventions used in describing peptide conformation.
Rotations about bonds are defined as torsion or dihedral angles that lie from -180° to
+180°. Rotation about the N-Ca bond is denoted by <t>; rotation about the C“-C' bond by
i|/; and rotation about C'-N by co. Table 1.1 shows the ideal <(>and y angles for the righthanded a-helix, antiparallel (3-sheet, parallel P-sheet and 3 10-helix. Table 1.2 shows the
dihedral angles for the residues in the y-tum and several representative P-tums. Often,
these values vary slightly in natural proteins, depending on the environment. These
variations in the dihedral angles maximize hydrogen bonding, hydrophobic/electrostatic
5
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> °
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Figure 1.3. Hydrogen bonding patterns in helices.
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Table 1.1
Dihedral angles for common secondary structures.1' 1

Bond Angle (deg)
0

V

0)

Right-handed a-helix

-57

-47

180

Antiparallel P-sheet

-139

+135

-178

Parallel P-sheet

-119

+113

180

3 I0-helix

-49

-26

180

Table 1.2
Common dihedral angles of selected y and P turns.1' 1

Dihedral Angles of C entral Residues (deg)a
Bend type
Classical y
Type T P

0i+l

¥«+i

70 to 85

-60 to -7 0

60

30

01+2
—

90

Vi+2
—

0

Type IT p
60
-120
-80
0
a The central residue of a y turn is numbered i + 2; the two central residues of a p turn are
/ + 2 and / + 3.
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Figure 1.4. Torsion angles of the peptide bond,
interactions within the protein and interactions between the protein and the aqueous
solvent. The values of <j>and y available to amino acid residues in a particular secondary
structure are indicated on a two-dimensional map of the $-\\i plane known as a
Ramachandran plot.1' 1
1.3 Antimicrobial Peptides
Antimicrobial peptides have been isolated from many different organisms including
insects, mammals, amphibians, bacteria and plants.1"7 Antimicrobial peptides contain
many structural similarities. While most are unstructured in aqueous media, many adopt
an amphipathic a-helix in membrane environments.1"8' 1' 10 Amphipathic alpha helices
possess a hydrophobic or non-polar face and a hydrophilic or polar face. Peptides that
contain an amphipathic a-helix tend to self-associate allowing the hydrophobic regions
to interact while exposing polar regions to the polar media. Figure 1.5 shows a Schiffer-

8
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Edmunson helical wheel diagram of the a-helix.1' 11 The wheel is shown looking down
the helix axis from the C-terminus to the N-terminus. P represents the polar residues
while N represents the non-polar residues.
Antimicrobial peptides are usually smaller than 40 residues long and contain
virtually equal numbers of polar and non-polar residues. As a result, the polar face is
usually less than 180°.1-10 Cationic residues occur more often than anionic residues
1 12

resulting in an overall positive charge at physiological pH. ‘
antimicrobial peptides have been extensively studied:
cecropms.

Three classes of

melittin, magainins, and

1.10,1.13

Isolated from the venom of the honeybee, Apis mellifera, melittin is a twenty-six
1 13

residue antimicrobial peptide. '

Like most antimicrobial peptides, melittin assumes no

observable secondary structure in aqueous media at low concentrations but adopts an
amphipathic a-helix at high concentrations or membrane environments.1' 10 Melittin
exhibits broad spectrum antimicrobial activity with minimum inhibitory concentrations
1 12

(MICs) in the pM range. '
use.

Melittin’s highly hemolytic nature limits its therapeutic

1.10

Cecropin A is a 37 residue antimicrobial peptide isolated form the North
American silk moth, Hyalophora cecropia. 1' 10 Cecropin A consists of two helical
regions. Helix 1 adopts an amphipathic a-helix structure while helix 2 remains largely
hydrophobic. This peptide exhibits high antimicrobial activity against representative
9
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Figure 1.5. Helical wheel diagram of an amphipathic a-helix.

Gram-negative and Gram-positive bacteria while showing no hemolysis at these
concentrations. 1.10
Magainin 2 is a twenty-three residue antimicrobial peptide isolated from the skin of
the frog Xenopus laevis.

It too adopts an amphipathic a-helix in membrane

environments. Magainin 2 possesses broad spectrum antimicrobial activities and is nonhemolytic at concentrations that are effective for antimicrobial activity.

1 14

1.4 Mechanisms of Action of Antimicrobial Peptides
The target of antimicrobial peptides is the phospholipid bilayer of bacteria. The
exact mechanism of action is not known. It is thought that the initial interaction between
10
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the peptide and bacteria is an electrostatic interaction.1' 15 Two mechanisms o f action on
membranes have been proposed: the raft or carpet model and the barrel-stave or pore
model.1' 15’ 116 Figure 1.6 shows each. In the raft model, the amphipathic a-helical
peptides first bind onto the surface o f the target membrane. The target membrane can
only be disrupted after a threshold peptide concentration has been reached. The peptide
does not insert into the hydrophobic core of the membrane but binds to the phospholipid
headgroups. The process of cell disruption via this method consists of four steps: (a)
preferential binding of positively charged peptide monomers to the negatively charged
phospholipid headgroups; (b) orientation of amphipathic a-helical monomers on the
surface of the membrane so that the positively charged monomers can interact with the
negatively charged phospholipid headgroups or water molecules; (c) partial insertion of
the peptide into the membrane so that the hydrophobic residues interact with the
hydrophobic core of the membrane; and (d) destroying the membrane by disrupting the
bilayer curvature leading to micellization.1' 16

In the pore model, transmembrane

amphipathic a-helices form bundles, in which their hydrophobic surfaces interact with
the lipid core of the membrane.

In this orientation, the hydrophilic surfaces point

inward, producing a pore. In this model, the peptide binding to the membrane is driven
by hydrophobic interactions. As a result, the peptide can bind to both zwitterionic and
charged phospholipid membranes. Membrane destruction via this mechanism involves
four steps:

(a) binding of the helical peptide monomers to the membrane; (b)

aggregation of the membrane bound monomers; (c) insertion of at least two assembled
monomers into the membrane to begin the pore formation; and (d) recruitment of
11
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additional monomers to increase the pore size leading to membrane disruption. Initial
assembly of the monomers must occur before insertion into the cell membrane as it is
energetically unfavorable for a single amphipathic a-helix to span the membrane as a
monomer.

1.16

1.5 Protein Structure and Amyloid Disorders
Many diseases are characterized by the presence of protein aggregates that form as
fibrillar structures known amyloid plaques. These plaques are rich in beta sheet
structures and insoluble under physiological conditions. Their presence may result from
genetic anomalies, accumulation of over the lifetime of the individual or exposure to
exogenous prion proteins. Among these diseases are Alzheimer’s disease (AD), type II
diabetes. Creutzfeldt-Jacob disease (CJD), Parkinson’s and Huntington’s diseases,
kuru and bovine spongiform encephalopathy (mad cow disease). There has been much
speculation about what role the fibrillar structures play in the pathology of these diseases.
Two theories have evolved to explain the presence of the structures. One posits that the
fibrillar structures are the causative agent of the diseases. The other suggests that the
fibrils are a result linked to the disease but are not the causative agent.

1 17-1 20

Many believe that the fibrils are the result of a normal protein misfolding to an
abnormal isoform. This abnormal isoform is rich in beta sheet structures resulting in the
formation of insoluble fibrils and protofibrils.

Several proteins can misfold, each

resulting in a different disease. For example, the protein associated with AD is the
amyloid p -peptide (AP) while the protein for CJD and other encepholapathies is the
1 17-1 19

prion protein (PrP). '

Since the amyloid plaques associated with all of these
12
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Figure 1.6. Mechanisms of action of antimicrobial peptides.1' 16
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diseases are comprised largely of beta sheets, it would be beneficial to study the factors
that form and stabilize this secondary structure. If these factors can be elucidated, it may
be possible to inhibit or even reverse the formation of the fibrillar structures linked to
many of these degenerative diseases.
The beta sheet is the second most common secondary structure found in peptides
and proteins, but relatively little is known about the factors that stabilize this structure.
I 21
Very few beta sheet models lend themselves to detailed study. '
Much of the recent
work done to study beta sheets has centered around synthesizing unnatural amino acids
to act as a turn thus nucleating beta sheet formation.

1 21-1 ^5

These amino acids are

successful in promoting beta sheets because they effectively tie the strands together, thus
overcoming entropy. As a result, the beta sheet formed is an intramolecular structure.
Kelly reports that while the entropy barrier is significant, the resulting hydrogen bonds
alone are insufficient to maintain the beta sheet structure.

I ’’ 2

It is believed that
1 22

hydrophobic interactions are also necessary to stabilize the structure. '

To date, there

are no known peptides that have been synthesized to reversibly form an intermolecular
beta sheet.
1.6 Peptide Synthesis
The synthesis of helical peptides requires amino acids that promote this secondary
structure. The many studies that have investigated the helix-promoting capacity of the
natural amino acids have focused on the frequency of these amino acids in helical
regions of proteins and peptides or on the effects of substituting a proteinogenic amino
14
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1 26-1 ?8
acid in the helical region of a peptide or protein. '
~ These studies found that
alanine, leucine, and lysine promote helical structures while proline and glycine break
...

. _

„

helical structures.

1.26, 1.27

As peptide length decreases, the proteinogenic amino acids that promote helicity do
so to the extent required. Other non-natural amino acids were then investigated for their
helix promoting ability. The first discovered was a-aminoisobutyric acid (Aib). Its
presence in the peptide, alamethicin, prompted investigators to postulate that Aib was a
strong helix promoter. Alamethicin was found to be more helical than was predicted
based on the natural amino acids.

1 29

It has been shown that residues that are disubstituted at the a-carbon like Aib, where
the R groups are not very large, promote helical structures.

The presence of the

additional R group limits the possible conformations of the residue in the peptide. As a
result, the rotation of the <j>, y angles is restricted. In the case of Aib, the angles are
limited to <j>= -60760° and y = -30730° for the left-handed and right-handed 3 10-helices.
For a-helices, 0 = -55755° and y = -45745° for the left-handed and right-handed
. ..

helices.

1.30, 1.31

Many other a,a-disubstituted amino acids (aaA A ’s) have been synthesized and
1 31-1 40

their effects on secondary structure studied. '

A series of a a A A ’s have been

studied in which the R groups on the a-carbon are identical and are not in a ring system.
Examples are diethylglycine, di-n-propylglycine, di-n-butylglycine, diphenylglycine and
dibenzylglycine. These amino acids, unlike Aib, promote extended conformations.
15
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1 31

While larger, acyclic R groups promote extended conformations, cyclic, aliphatic
a aA A ’s can promote helical structures.

1-Aminocyclobutane carboxylic acid, 1-

aminocyclopentane carboxylic acid, 1-aminocyclohexane carboxylic acid and 1-amino
cycloheptane carboxylic acid promote helical

formation.

1-Aminocyclooctane

carboxylic acid forms a 3,0-helix or (3-bend structure while 1-aminocyclopropane
131 1 33

carboxylic acid forms a distorted 3,0-helix. ‘ ’

In order to study amphipathic peptides containing a aA A ’s, several polar a a A A ’s
1 37-1 40

have been synthesized. '

These polar a a A A ’s are believed to promote the same

secondary structures as their non-polar counterparts. Orthogonal protection of the side
chain with respect to the a-amine or carboxylic acid is necessary for the incorporation of
the amino acid into a peptide. As a result, incorporation of polar aaA A ’s allows one to
synthesize water-soluble peptides that contain high percentage of aaA A ’s. In turn, these
peptides can be designed to be amphipathic and used for biological studies.
1.7 Incorporation of a,a-Disubstituted Amino Acids Into Peptides
1 32

Incorporating aaA A ’s into a peptide has proven difficult. '

The additional R

group on the a-carbon substantially increases steric bulk, making oaA A couplings
1 41

difficult. '

Traditional coupling reagents such as carbodiimides (i.e. dicyclohexyl

carbodiimide or diisopropyl carbodiimide) or 1-hydroxybenzotriazole (HoBT) rarely
1 42

improve the yields of aaA A couplings. ‘

In addition, (benzotriazolyloxy)-tns-

(dimethylamino) phosphonium hexafluorophosphate or O-benzotriazolyl-M N, N ' N tetramethyluronium hexafluorophosphate have not improved coupling yields.
16
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1 41

As a result of the limited success in a a A A couplings, new methods have been
pursued to improve coupling yields. Acid chlorides, oxazolones, N-carboxyanhydrides
1 41

(NCA’s) and 2-(dimethylamino)-3,3/-dimethylozirine are a few of the methods used. ‘ '
1 43 1 44

' *

Each of these methods has improved a a A A coupling yields but each suffers

disadvantages. Acid chloride use is limited because of harsh conditions for its formation
1 43

and its tendency to form oxazolones. '

NCA’s and oxazolones suffer from side

product formation accompanying the couplings. Hydrolysis following azirine coupling
1 41 i 44

severely limits its usefulness in peptide synthesis. * ’

Some degree of success has been recently achieved in improving a a A A coupling
yields. The most noted are the use of acid fluorides or other coupling reagents such as 7azabenzotriazole- l-yloxytris(pyrrolindino)phosphonium hexafluorophosphate (PyAOP)
or

N-[[dimethyl

amino-)-1H-1,2,3-triazole[4,5-b]pyrindin-1-yl]methylene]-N-

methylmethanaminium hexafluorophosphate N-oxide (HATU).1'41’ 145 148 The acid
fluoride method developed by Carpino can give high aaA A couplings under mild
conditions and is useful in either solution phase synthesis or solid phase peptide
141

synthesis (S P P S ).

1 45 1 46

The preformed acid fluorides are reacted with the free

amine of another amino acid in the presence of base (e.g., N, N-diisopropylethylamine,
DEEA). The acid fluoride can be prepared by treating the amino protected amino acid
with cyanuric fluoride and pyridine or in situ with tetramethylfluorformamidinium
hexafluorophosphate (TFFH).

149-151
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1.8 Effects of a,a-Disubstituted Amino Acids on Secondary Structure
As mentioned previously, the three major secondary structures are the a-helix, 3 I0helix and beta sheet. a a A A ’s have been shown to promote each of these structures. The
beta sheet is usually promoted by aaA A ’s that have large, bulky a-substitutents.1'31
Cyclic a a A A ’s, with 8-membered or smaller rings, and aaA A ’s with a methyl group as
one of the a-substitutents promote 3,0-helices or a-helices. The preference for which
helix type depends on the peptide design, the environment, location and number of
aaA A ’s.
Many groups have studied the equilibrium between 3I0- and a-helices because the
3I0-helix is thought to be a folding intermediate to the a-helix and is thought to play a
role in receptor binding.1'52 155 Several studies have been done which characterize
both helix types in short peptides containing a a A A ’s .1'53 1 55 Until recently, the use of
hydrophobic amino acids has prevented studies in aqueous media.
Many factors have been postulated for the prediction of the type of helix formed in
short peptides rich in a a A A ’s.

The length o f the peptide, percentage of a a A A ’s,

location of monosubstituted amino acids, and the solvent effects are among the major
1 44

factors believed to be involved in the 3io/a-helix equilibrium. '

1 5"M 59

Peptide

length is believed to play an important role in helix preference. Karle reported that Aib
rich peptides with five residues or less form 3i0-helices, while peptides with ten or more
residues form a-helices.

1 53

Aib rich peptides between five and ten residues do not
18
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appear to have a helix preference but many still believe peptide length is an important
factor in preferential helix formation.

131 1 53

The percentage of a a A A ’s incorporated in a peptide is also believed to have an
influence on helix formation. This factor is significant for medium length peptides (7-10
residues) which can form either a 310-helix or an a-helix. Peptides with at least seven
residues and 50% or more a a A A ’s form a 3i0-helix while those containing less than
50% aaA A content favor an a-helix.

1 53

It has been suggested that the location of monosubstituted amino acids in aaA A rich
peptides is more important on the helix preference than the percentage of a a A A ’s.

1 44

This factor was studied using peptides containing 75% Aib residues. Incorporating two
monosubstituted amino acids consecutively in the peptide sequence resulted in 310-helix
formation.

1 44

Helix preference may also be influenced by the media surrounding the peptide. The
polarity of organic solvents used in crystallization and NMR studies has influenced helix
preference.1'55’ 157 159 One experiment performed on an Aib rich peptide showed ahelix formation in dimethyl sulfoxide (DMSO) while the helix type shifted to a 310-helix
when chloroform was used.1'57 Another experiment with Aib rich peptides showed an
a-helix is preferred when water is present and a 3i0-helix is preferred under anhydrous
conditions.

158 1 59
’

In crystallization experiments, an a-helix and 3i0-helix was

obtained using methanol and methanol/ethyl ether solvent systems respectively.1'55

19
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Based on these studies, it appears that polar solvents favor an a-helix while less polar
solvents favor a 310-helix.
Theoretical calculations have been performed to further probe the effects of solvent
polarity on helix preference.

The a-helix appears to be favored thermodynamically

while the 3I0-helix is favored entropically. The theoretical studies confirm what has been
observed experimentally. Specifically, the 3i0-helix is favored in short, Aib-rich peptides
while the a-helix is favored in longer peptides. In addition, the two helix types have the
same energy in peptides with a length of 7.5 residues. This agrees with the observed data
presented by Karle and others who report an equal helix preference for peptides between
seven and ten residues.1’53, 1-56 For peptides of this length, the solvent significantly
affects the 3 10-/a-helix equilibrium.
To study the solvent effects on 3I0-/a-helix equilibrium, four media, vacuum,
methylene chloride, acetonitrile, and water were examined using a poly-Aib 10-mer
peptide. In lower polarity environments, the 3i0-helix is slightly more stable. As the
polarity of the media increases, the a-helix becomes more stable. The correlation of ahelix stability to increasing solvent polarity can be attributed to peptide-solvent
interactions.

In a ten-residue peptide, the a-helix forms six intramolecular hydrogen

bonds. This leaves three N-terminal amide hydrogens and four C-terminal carbonyl
oxygens without internal hydrogen bonding partners. In a ten residue 3i0-helix, seven
intramolecular hydrogen bonds are possible. This leaves two N-terminal amide protons
and three C-terminal carbonyl oxygens without hydrogen bonding partners (Figure 1.3).
As a result of the additional exposed carbonyl and amide protons, the a-helix has more

20
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favorable interactions with the solvent thereby increasing stability.

In non-polar

environments, the 3 i0-helix gains stability form the extra intramolecular hydrogen bonds
present as compared to the a-helix.1'56
1.9 Characterization of Peptide Secondary Structure
There are several techniques, such as X-ray crystallography and NMR for the
characterization of secondary structure. However, neither is as convenient and reliable
as circular dichroism (CD). In ultraviolet-visible light spectroscopy, organic molecules
absorb radiation via the promotion of electrons to higher energy molecular orbitals.
Circular dichroism takes advantage of this phenomenon and carries it one step further.
Optically active (i.e., chiral) organic molecules rotate plane-polarized light. Plane
polarized light can be resolved into its two circularly polarized components:

left

circularly polarized light (LCP) and right circularly polarized light (RCP). The electric
vector of LCP rotates counterclockwise about the axis perpendicular to the direction of
travel of the light beam while the electric vector of RCP rotates clockwise.

A chiral

molecule produces a circular dichroism spectrum because its absorption of LCP is not
equal to its absorption of RCP. After passing through a chiral medium, the electric
vectors describe an ellipse whose major axis lies along a new angle of rotation. The
measured eccentricity of the ellipse represents the unequal absorption of LCP and RCP
referred to as circular dichroism. Analogous to Beer’s law, the experimentally measured
ellipticity is equal to 6cd where 6 is the molar value in radians, c is the molar
concentration and d is the cell path length in centimeters. A circular dichroism spectrum
plots the molar ellipticity versus wavelength.

1 60-1 62
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CD is useful in determining the secondary structure of peptides because in the
absence of aromatic amino acid residues, only the peptide backbone contributes
significantly in the far UV region as the spectrum reflects the spatial arrangement of
chiral units in the peptide chain.

The presence of aromatic amino acids induces a

positive CD signal, causing significant errors in ellipticity values.1'63 1-65 The three
main classes of secondary structure, the alpha helix, 310-helix, and beta sheet as well as
the random coil, can be distinguished by their CD spectra. Figure 1.7 shows the typical
CD spectrum for each of these secondary structures.1'61
Helical peptides, the a-helix and 3 i0-helix, exhibit two minima near 208 nm
(k —

and 222 nm (n—»7t*|) and a positive band near 195 nm (tc—>7C*_L). The 310-helix

and the a-helix spectra are very similar but can be easily distinguished. The ratio, R, of
the intensity of the 222 nm band divided by the intensity of the minimum near 208 nm is
used to differentiate between the 3i0-helix and the a-helix. The ratio is approximately 1
for the a-helix, while the ratio is 0.4 or less for the 310-helix. Also, the positive band
near 195 nm is much weaker for the 3i0-helix as compared to the a-helix. Few CD
spectra o f 3 10-helices have been reported. To date, experimental spectra reported agree
well with the theoretically calculated 3i0-helix CD spectra.1'60' 166~1-69
The (3-sheet and random coil, are easily distinguished from each other. The |3-sheet
exhibits a negative band near 217 nm representing an n—>it’ transition and a positive
band near 195 nm representing a jc—>tc* transition. The random coil exhibits a strong
negative band near 197 nm (jc-mc*) and a small positive band at 217 nm (n—mc’).1'60
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Peptide conformation is highly sensitive to solution variables; a peptide may be
insoluble in one condition, but well behaved under others.

In characterizing the

secondary structure of peptides by CD, the effect of pH, ionic strength of the buffer and
peptide concentration should be examined. As a general rule, aggregation increases with
peptide concentration, ionic strength or pH. Concentration dependence reveals whether
the peptide is monomeric or self-associating. For example, a shift from random coil to
beta sheet as the peptide concentration increases indicates an association equilibrium.
Self-association may be obtained by changing pH (usually increasing) to titrate the
amino groups present in the peptide sequence or by changing the ionic strength of the
buffer to optimize charge screening.

Variations in these parameters are examined

systematically in an effort to determine the number and type of species present in the
solution. Stable equilibrium between only two states are identified by the presence of an
.

.. .

.

isodichroic point.

1.60 . 1.61
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Chapter 2
a , a-Disubstituted Amino Add Rich Peptides Active Against Intracellular
Pathogens
2.1 Introduction
While antibiotics have saved countless lives by fighting bacterial infections, bacteria
o 1-2 3

are increasingly resistant to their effects.”'

This has stimulated the search for new

antimicrobial agents with modes of action different from those of known antibiotics.
■j 4

Antimicrobial peptides are thought to be one solution to this problem.- '

Though the

mechanism of action of these peptides is still debated, there is agreement that they
2 5-2 7

disrupt the cell membranes of susceptible cells. '

The reason for this selectivity is

also unclear but it has been postulated that exterior membrane charge differences,
membrane potential differences, cholesterol content and differences in the rate of
2 8-^ 12
membrane repair contribute to the selective activity of the peptides. ' “'
There is also
evidence that there is a distinction between antimicrobial peptides (those with direct
action against bacteria) and cytotoxic peptides.

Cytotoxic peptides, as well as
2 11 2 13

antimicrobial peptides, have activity against altered mammalian cells. '

’ '

This

result is intriguing as it suggests the possibility of using cytotoxic peptides to treat
intracellular pathogens, which are especially difficult to eliminate because conventional
2 14

antibiotic therapy and the host’s immune response are ineffective. '

Brucella abortus

(Ba) and Mycobacterium tuberculosis (Mtb) are intracellular pathogens that live and
replicate within the macrophages of their hosts.

2 15
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The veterinary pathogenic brucella species, B. abortus, B. melitensis, B. suis and B.
2 16 2 17

canis are also pathogenic for man. ' ’ '

They are short, non-motile, non-sporulating

and non-encapsulated Gram-negative aerobic rods. In animals, brucella localizes in the
reproductive organs, supramammary lymph nodes and other reticuloendothelial tissues
2 18

resulting in abortion and infertility. ’

In humans, infection leads to a chronic,
2 19

debilitating disease known as undulant fever. '

Human infection may result from
2 20

exposure to infected animals or infected animal products. ‘

As a result, brucellosis is

an occupational hazard for veterinarians, abattoir workers, animal handlers and
2 21

laboratory staff. '

The brucella species is easily spread via aerosolization, making

them good candidates for biological weapons.

2 22

Undulant fever is characterized by general malaise, fever, anorexia, muscular
2 19

weakness, arthritis and dementia. '

Other disorders associated with the disease include

cardiac and neurologic disorders. If untreated, undulant fever is fatal in about 10% of
the cases. Current treatment consists of lengthy antibiotic therapy with one or more
drugs for 30 to 45 days. Relapses often occur after the treatment is stopped and the
antibiotics do not relieve the symptoms. The vaccines used to control brucellosis in
animals are not available for use in humans as they are virulent to man.
Brucella abortus is an intracellular pathogen that lives and replicates in a host’s
2 23-2 '’ S

macrophages. ‘

The ability to survive in a host’s macrophages is a key element in
2 26

allowing the organism to cause disease. '

Intracellular brucellae are hidden from the

30
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immune responses of the host and are not directly exposed to the complement cascade,
7

neutrophils, brucella specific antibodies or conventional antibiotics.''

27

Brucellosis

requires alternative treatments.
Diseases caused by other intracellular pathogens would be potential targets for
treatments developed for brucellosis.

For example, the mycobacterium species of

bacteria are intracellular pathogens that cause diseases that have etiologies similar to
brucellosis.

Mycobacterium tuberculosis, the causative agent o f tuberculosis (Tb),

infects about a third of the world’s population and kills more people than any other
2 28

infectious agent. '

Mtb is a rod-shaped, acid-fast bacterium that localizes mainly in

the respiratory systems of animals. The symptoms of tuberculosis include low-grade
fever, night sweats, fatigue, weight loss and persistent cough. Tuberculosis is spread via
2 28

aerosolization of the bacteria as a result of a cough or sneeze. '

Like Ba, Mtb can live

and replicate within a host’s macrophages, making it especially difficult to treat. Current
treatment consists of a prolonged regimen of multiple antibiotics.

Many strains of

mycobacterium now resist antibiotics, making the development of alternative treatments
critical.
2.2 Cell Mediated Immune Responses to Intracellular Pathogens
Antimicrobial peptides have mechanisms of action different from that of
antibiotics, thus making them interesting targets for drug design.

Infection of

mammalian cells by intracellular pathogens is particularly difficult to treat with
conventional antibiotics alone due to the body's inability to completely eliminate the
pathogens. In order to understand the significance of a novel mechanism o f action by an
31
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antimicrobial peptide, a review of the immunology of intracellular pathogen infection is
warranted.
One of the body’s responses to an infection is to engulf the invading bacteria
using macrophages (M<|>).

Some of the macrophages kill the bacteria and process

bacterial antigens for display on the major histocompatibility complex (MHC). CD4+ Tcells differentiate into TuTH-cells (DTH = delayed-type hypersensitivity) within two to
several weeks after infection.
macrophages.

Figure 2.1 shows how the T DTH-cells target infected

The Tdth-ccIIs recognize the infected macrophages presenting the

bacterial antigen, which results in the invasion of a large number of activated
macrophages. The activated macrophages sequester the infection inside a granuloma
consisting of a few Torn-cells and many activated macrophages. The macrophages may
differentiate into epitheloid cells or multinucleated giant cells. Figure 2.2 shows the
anatomy of a granuloma.

The activated macrophages usually repress the infection.

Cytokines produced by TDTH-cells inhibit further spread of the infection.

IFN-y is

important in the body’s response to mycobacterium infection. Knockout mice lacking
IFN-y died even when infected with an attenuated strain of Mycobacterium sp. (Bacillus
Calmette-Guerin). Normal mice possessing IFN-y survive this infection. Macrophages
presenting bacterial antigens are also attacked by CD8+ T-cells that differentiate into
cytolytic T-cells. Figure 2.3 shows the development and killing mechanism of cytolytic
T-cells. The cytolytic T-cells release granules near the cell marked for eradication. The
granules contain perforin monomers that oligomerize into large pores on the cell
membrane, resulting in lysis of the cell. These immune responses are effective only
against macrophages that process the intracellular pathogen and present bacterial
32
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antigens. Infected cells that fail to process the intracellular pathogen will harbor the
infection.

The

infection

becomes

hypersensitivity in most people.

asymptomatic

after

the development of

Furthermore, quiescent granuloma can also harbor

viable intracellular pathogens, especially in the case of tuberculosis.

2 ^9

2.3 Results
Table 2.1 lists the de novo amphipathic peptides used in this study. They are
comprised of 80% a,a-disubstituted amino acids (aa A A ’s) and a natural amino acid
residue. The design is based on antimicrobial peptides that occur in nature with the
incorporation of the a a A A ’s to promote helicity.

Table 2.2

lists several naturally

occurring antimicrobial peptides. Studies have shown that amphipathic peptides with at
2 30 2 31

least eighteen residues can have high cytotoxicity. ' ’

Shortening the peptides to

fourteen residues reduces cytotoxicity but maintains most of the antimicrobial
2 30 2 31

activity. ' ’

The peptides under discussion were part of a series of peptides

synthesized in our lab to test the hypothesis that a-aminoisobutyric acid, Aib and Aiblike residues would stabilize helical conformations and maintain biological activity as
2 32

the peptide length was decreased. '

Various combinations of lysine with Aib, 1-

amino-l-cyclohexanecarboxylic acid, Cyh, and 4-aminopiperidine-4-carboxylic acid,
Api, were used in the peptides. Figure 2.4 shows the structures of these amino acids.
The peptides were synthesized using acid fluorides developed by Carpino.

2 33-2 35

The peptides were synthesized on a Milligen 9050 peptide synthesizer using
PAL-PEG-PS support. The reactions were carried out in N,N-dimethylformamide
33
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Figure 2.1. Delayed-type hypersensitivity (DTH) immune response.
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F igure 2.2. Anatomy of a granuloma.
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Figure 2.3. Development and killing mechanism of cytolytic T cells.
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2 29

h 3c

CH3

H,^

CO,

Aib

Api

Cyh

Figure 2.4. Structures of Aib, Cyh and Api amino acids.

Table 2.1
Sequences of de novo peptides.
Peptide

Sequence

Pi-10

Aib-Aib-Api-Lys-Aib-Aib-Api-Lys-Aib-Aib-NH2

Ipi-10

Api-Aib-Aib-Lys-Aib-Aib-Lys-Aib-Aib-Api-NH2

Cyh-10

Cyh-Cyh-Api-Lys-Cyh-Cyh-Api-Lys-Cyh-Cyh-NH2

Ich-10

Api-Cyh-Cyh-Ly s-Cyh-Cyh-Lys-Cyh-Cyh-Api-NH2

37
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Table 2.2
Sequences of naturally occurring antimicrobial peptides.
Peptide
Melittin

Cecropin B amide

Magainin 2 amide

Sequence
Gly-De-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-ProAla-Leu-ne-Ser-Trp-ne-Lys-Arg-Lys-Arg-Gln-Gln-NH2
Lys-Trp-Lys-Val-Phe-Lys-Lys-Ile-Glu-Lys-Met-Gly-Arg-Asnne-Arg-Asn-Gly-De-Val-Lys-Ala-Gly-Pro-Ala-Ile-Ala-ValLeu-Gly-Glu-Ala-Lys-Ala-Leu-NH2
Gly-De-Gly-Lys-Phe-Leu-His-Ser-Ala-Lys-lys-Phe-Gly-LysAla-Phe-Val-Gly-Glu-He-Met-Asn-Ser-NH2__________________

(DMF) using 8 equivalents of the 9-fluorenylmethyloxycarbonyl (Fmoc)-amino acid
fluorides, and 3 equivalents of diisopropylethylamine (DIEA). The amino acids were
allowed to couple for 1.5 hours. Removal of the Fmoc protecting group was done using
a solution of 2% l,8-diazobicyclo[4.5.0]undec-7-ene (DBU), and 20% piperdine in
DMF. Deprotection of the side chains and cleavage from the resin was accomplished
simultaneously by treatment with trifluoroacetic acid (TFA), triisopropylsilane, water,
2 36

and phenol (8.8:0.2:0.5:0.5) (reagent B) for 2 hours. '

Purification of the peptides

was done by preparative reverse-phase HPLC on a C4 column using a gradient of water
and acetonitrile with 0.05% TFA in each. Molecular weight and amino acid composition
were verified by MALDI mass spectrometry and amino acid analysis, respectively. The
peptides were synthesized by manually coupling the first three residues on PAL-PEG-PS
resin using eight equivalents of the amino acid fluoride and two equivalents of DIEA in
gently reflu xing methylene chloride (DCM). The reaction was monitored by removal of
small aliquots o f resin followed by work-up to determine the level of Fmoc-piperidine
38
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adduct present relative to the expected amounts.

2 37

After the first three couplings were

completed, the remainder of the sequences was synthesized on the Milligen 9050. The
direct antimicrobial activities of the peptides were tested against representative Grampositive (S. aureus) and Gram-negative (E. coli) bacteria. Table 2.3 summarizes the
results.

Table 2.3
Peptide antimicrobial activity.
Peptide

M IC (pM ) vs. E. coli

M IC (pM ) vs. S. aureus

P i-10

8

123

Ipi-10

4

Not active

Cyh-10

6

6

Ich-10

13

3

Melittin

3

3

Cecropin B amide

1

12

Magainin 2 amide

10

19

Chronically infected mice are susceptible to peptide toxicity at lower doses than
healthy mice. For melittin, the highest non-lethal dose was 25 pg. For Aib containing
peptides (P i-10 and Ipi-10), the highest non-lethal dose was 500 pg. For Ich-10, the
highest non-lethal dose was 25 pg. The toxicity estimations were grouped into three
categories: none, stress and toxic. None meant the peptide showed no apparent effect on
the peptide-treated, non-infected mice as compared to the saline-treated infected mice.
39

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Stress was used to indicate that the mouse showed signs of distress: i.e. tremors,
temporary paralysis, etc. Toxic meant that some of the mice in that treatment group died
at the lowest dose that still reduced spleenic brucella levels.
Peptide doses were titrated to the lowest effective dose; however, several of the
infected mice died at peptide doses that were harmless to the control mice. The mice
usually died within 1-2 minutes of injection from massive internal bleeding. Table 2.4
shows the indirect in vivo activity of the peptides against Brucella abortus in BALB/c
mice.
Table 2.5 shows percent normal murine macrophage survival versus peptide
concentration. Pi-10 shows little toxicity at all concentrations tested while Ich-10 was
very toxic at 100 pM and less so at 10 pM. For comparison, melittin is very toxic at 10
pM. For the in vitro studies, doses that showed > 70% macrophage survival were used
as the starting dosages to determine if infected macrophages are selectively destroyed
relative to non-infected macrophages. The data is shown in Table 2.6.
Murine macrophages were incubated with B. abortus, which infects approximately 40%
2 24
of the macrophages. ‘
The survival rate (90%) of this partially infected macrophage
population was the same as the normal non-infected macrophage survival rate over a 48hour period. Melittin shows slightly lower survival of infected macrophages while the
remaining peptides show significantly lower survival of the infected macrophages. Pi-10
shows an approximately 40% lower macrophage survival rate of the partially infected
population.

This

agrees

with

the

maximum expected since about 40% of the

macrophages are infected. Ipi-10 and Ich-10 kill less and more than the expected ideal
value of 40%, respectively.
40
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Table 2.4
Indirect in vivo activity against Brucella abortus in BALB/c mice.
Toxicity

500

% Brucella
Reduction
90

Ipi-10

500

55

Stress

Cyh-10

ND

ND

ND

Ich-10

25

82

None

Melittin

25

50

None

Cecropin B amide

500

53

None

Magainin 2 amide

500

54

None

Peptide

Dose (pg)

Pi-10

None

Table 2.5
Normal macrophage survival versus peptide concentration.
Peptide

100 pM

10 pM

1 pM

Pi-10

91

96

97

Ich-10

0

77

100

Melittin

ND

<2

ND

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Table 2.6
In vitro peptide toxicity against normal and infected murine macrophages.
Peptide

Cone (fiM)

% Survival
Infected M<t>’s
55

Statistical
Significance*
S

Pi-10

10

% Survival
Normal M<t>’s
90

Ipi-10

50

90

80

s

Ich-10

25

95

20

s

Melittin

0.1

85

78

s

a Independent student’s t-test at a 95% confidence level.

To test the hypothesis that these peptides selectively destroy infected
macrophages over non-infected macrophages, in vitro studies were performed using a
strain o f Ba containing a green fluorescent protein (GFP) and a strain of Mycobacterium
chelonei (Mch). Ba is too small to be seen at the magnification levels used to visualize
the macrophages; therefore, the strain expressing the GFP allows the infected
macrophages to be identified. Mch is a relatively large microorganism and is easily seen
inside the macrophages. Table 2.7 summarizes the results using P i-10 and Ich-10.
Figures 2.5 to 2.15 are photomicrographs of the macrophages used in this portion
of the study. Trypan blue exclusion was used to visualize dead macrophages. Figure 2.5
is a photograph of normal, healthy macrophages. Figure 2.6 shows a fluorescence
42
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Table 2.7
In vitro peptide activity against control and infected macrophages.
Peptide

Dose (pM)

Pi-10

Statistical
Significance*

—

% Survival
Ba Infected
M<t>
99.6 ± 0 .6

% Survival
Mch Infected
M<(>
97.0 ± 3 .0

Ich-10

—

95.0 ± 2.0

N/A

Pi-10

100 pM

80.3 ± 3.5

72.8 ±5.1

S

Ich-10

50 pM

81.0 ± 1.0

N/A

s

a Independent student's t-test at a 95% confidence level

photograph of healthy macrophages.

Figure 2.7 shows a Nomarski photograph of

macrophages infected with Ba-GFP. Figure 2.8 is a fluorescence photograph of the
macrophages infected with Ba-G FP. Figure 2.9 shows uninfected macrophages treated
with 100 pM Pi-10.

Figure 2.10 shows a fluorescence photograph of uninfected

macrophages treated with 100 pM P i-10.

Figure 2.11 is a Nomarski photograph of

macrophages infected with fta-GFP and treated with 100 pM Pi-10. Figure 2.12 shows
a fluorescence photograph of the macrophages infected with fla-GFP and treated with
100 pM Pi-10.
To test the theory that the peptides are active against macrophages infected with a
different intracellular pathogen, studies were carried out using Mycobacterium chelonei.
Mch was used instead of Mtb as it is less virulent to man than Mtb. Figures 2.13 to 2.15
show the results of this study. Figure 2.13 shows macrophages that have been infected
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Figure 2.5.

Nomarski photomicrograph of healthy macrophages.
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Figure 2.6.

Fluorescence photomicrograph of healthy macrophages.
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Figure 2.7.

Nomarski photomicrograph of untreated macrophages infected with BaGFP.
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Figure 2.8.

Fluorescence photomicrograph of untreated macrophages infected with
fla-GFP.

47

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 2.9.

Nomarski photomicrograph of treated, uninfected macrophages.
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Figure 2.10.

Fluorescence photomicrograph o f treated, uninfected macrophages.
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Figure 2.11.

Nomarski photomicrograph of peptide treated macrophages infected with
Ba-GFP.
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Figure 2.12.

Fluorescence photomicrograph of peptide treated macrophages infected
with Ba-G FP.
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Figure 2.13.

Nomarski photomicrograph of untreated macrophages infected with Mch.
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Figure 2.14.

Nomarski photomicrograph of peptide treated macrophages infected with
Mch.
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Figure 2.15. Nomarski photomicrograph of peptide treated macrophages infected with
Mch which shows cell membrane disruption.
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with Mch. Figures 2.14 and 2.15 show macrophages infected with Mch that have been
treated with 100 pM Pi-10.
2.4 Discussion
It is well known that basic amphipathic a-helical peptides exhibit in vitro
antimicrobial activity at pM concentrations.

The hydrophobic peptides in this class

usually display high mammalian cell toxicity. A good example o f this class of peptides is
melittin. It is an amphipathic peptide with a relatively narrow polar face and possesses
2 38

high cytotoxicity. ‘

De novo peptides have been designed to mimic melittin and those

containing hydrophobic and hydrophilic residues such as leucine and lysine are among
2 39

the most cytotoxic known. '

It has been shown that cytotoxicity depends on the length

of the peptide as well as hydrophobicity. As the peptide length is decreased, cytotoxicity
also decreases. Our group has demonstrated this phenomenon using a series of de novo
hydrophobic, amphipathic peptides.

Cytotoxicity was almost eliminated when the

peptides were shortened from 21 residues to 14 residues. Interestingly, direct in vitro
antimicrobial activity was essentially retained in the shorter peptides.

2 31

Using the knowledge that shorter, more hydrophobic helical peptides could retain
biological activity with reduced cytotoxicity, it was hypothesized that otaAA’s could be
used to design shorter, helical peptides.

Since ocaAA’s promote helicity, their

incorporation into very short hydrophobic peptides should lead to more selective and
2 40-2 43

more biologically active peptides. '

A problem with this approach is the difficulty

associated with incorporation of a a A A ’s using conventional peptide coupling

55

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

2 43

reagents. '

This problem has been solved with Carpino’s development of acid

fluorides for amino acid couplings. This method allows for the mild and efficient solidphase synthesis of peptides containing multiple a a A A ’s.

i 33

Despite the improved

coupling method, difficulties in the synthesis of the peptides were still encountered. The
second residue in P i-10, Ipi-10, Cyh-10 and Ich-10 did not couple efficiently. This is
presumably due to steric difficulties in coupling two aocAA’s together near the resin.
The problem was resolved by gently refluxing the first three couplings in methylene
chloride with DIEA. Each coupling was monitored by quantitative Fmoc tests until at
least 95% coupling efficiency was indicated. Once the third residue was satisfactorily
coupled, the remaining residues were coupled using the Milligen 9050.
A maximum number of aaA A ’s was desired in each peptide to promote helicity.
To achieve this and maintain a high number of positive charges on the polar face, the
aaA A , Api, was used.

2 33

A peptide consisting only of a aA A ’s would be difficult to

synthesize and would present problems in our spectroscopic studies. Since the a a A A ’s
are achiral, the resulting peptides would have no preference for a right-handed or lefthanded helix. As a result, two L-lysine residues are used in each peptide.
It has been shown that peptides that contain Aib residues are significantly more
helical than peptides that are comprised only of natural amino acids. The replacement of
natural amino acids with Aib also substantially improved antimicrobial activity against
E. coli and S. aureus.

2 31

Pi-10 shows a significant improvement in activity over
2 32

peptides containing only proteinogenic amino acids. '

This increase in activity is
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attributed not only to the improved helicity but the increase in hydrophobicity that Aib
gives the peptide.

Ipi-10, a sequence permutation isomer of P i-10, shows similar

activity. To study the effects of hydrophobicity on peptide activity, Cyh-10 and Ich-10
were synthesized. In these peptides, the Aib residues are replaced with Cyh residues. As
can be seen in Table 2.3, these peptides have similar activity against E. coli but are up to
41 times more active against S. aureus.
The in vitro studies provided us with some background regarding what to expect
in the in vivo studies. Melittin proved to be the most cytotoxic peptide in the in vitro
studies. It is the most active peptide in vivo with effective dosages at 25 pg per mouse.
The in vivo studies were carried out by injecting the peptides in the lateral tail vein which
should rapidly carry the peptide to the primary site of infection, the spleen.

It was

thought that melittin would indiscriminately attack all cells in the blood but in normal,
non-infected mice, this did not occur. However, when similar doses of melittin were
administered to infected mice, they died within 1 to 2 minutes of injection. Necropsy of
these mice showed massive internal bleeding with the lungs filled with blood.
Apparently, the mice died of sepsis associated with the simultaneous lysis of a large
number of macrophages releasing nitric oxide and cytokines.

Similar behavior was

noted for Ich-10, which is expected due to its increased hydrophobicity. An injection of
50 pg into an infected mouse resulted in death.
The de novo peptides were tested in vitro against normal and infected murine
macrophages. Macrophages were harvested from the spleens of normal mice and plated
out in 96 well plates. Trypan blue exclusion was used as an indicator of macrophage
viability.

About 90% of the plated out macrophages survived the stress of this
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manipulation, so only survival percentages less than 90% indicate peptide toxicity.
These experiments were performed to determine the peptide concentrations to be used
against the infected macrophages. P i-10 and Ich-10 were tested at 1 to 100 pM. P i-10
was non-toxic at 10 pM whereas Ich-10 was non-toxic at 1 pM . Melittin is non-toxic at
0.1 pM owing to its length and hydrophobicity. The macrophages plated out as above
were infected with B. abortus for one hour. The excess brucellae were washed away
leaving behind intracellular brucellae. Brucella counts indicated that approximately 40%
of the macrophages were infected. This percentage of experimental brucellae infection is
2 20

consistent with literature values. '

The macrophages had the same viability pre- and 1

to 48 hours post infection as determined by trypan blue exclusion. Peptide effects on
macrophage survival at the doses determined above were assayed. Table 2.6 shows that
melittin, Ich-10 and Pi-10 are effective in selectively killing infected macrophages over
non-infected macrophages.

Ich-10 and melittin are effective at much lower

concentrations than Pi-10 presumably due to their increased hydrophobicity.

Ich-10

deviates slightly from the ideal value of 55%, suggesting that the optimal dose is lower
than that tested.
To further test the hypothesis that the peptides selectively destroy infected over
non-infected macrophages, the above in vitro studies were repeated using a strain of B.
abortus containing a green fluorescent protein. In addition, in vitro studies were carried
out using M. chelonei to verify that these peptides were effective against a different
intracellular pathogen. P i-10 was the only peptide used in this study since it showed the
most selectivity for killing infected macrophages. The macrophages were harvested and
plated out as before. Infection with Ba-GFP and Mch were also carried out as before.
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Macrophage assays reveal that a similar percentage of macrophages were infected with
both intracellular pathogens. The intracellular brucellae are too small to visualize with
conventional light microscopy. The Ba containing the green fluorescent protein allows
them to be visualized inside the macrophages using fluorescence microscopy. Mch is
large enough to be seen inside the macrophages using conventional light microscopy.
Each study was repeated as before to show that there was no difference in using the
normal strain of Ba vs. Ba-GFP or Mch. The data on the non-infected peptide treated
and infected non-peptide macrophages was within experimental error of that done for
previous studies.

Figures 2.5 to 2.15 show photomicrographs of these results. The

infected macrophages were then treated with 100 pM of P i-10 for one hour. Excess
peptide was washed away, trypan blue was added and allowed to stand for 5 minutes.
The excess trypan blue was removed and the macrophages were assayed. Figures 2.11
and 2.12 show the Nomarski and fluorescence photographs of the same region of a 96
well plate. As can be seen in Figure 2.11, the blue cells are dead. Figure 2.12 reveals
that these cells were infected with fla-GFP, making them susceptible to the peptide.
There appears to be several cells that exhibit fluorescence and are not dead. This may be
the result of slight auto-fluorescence of the cell that is not infected or insufficient peptide
dose to kili the macrophage, which is infected. Figure 2.13 reveals several macrophages
that are infected with Mch. The bacteria appear as rod-like structures. Figures 2.14 and
2.15 show that the macrophages possessing these organisms have been destroyed by the
peptide, leaving other macrophages intact.
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2.5 Experimental
2.5.1 Peptide Synthesis
Cyh-10 and Ich-10 were synthesized by manually coupling the first three residues
onto a PAL-PEG-PS solid support. The couplings were done by refluxing 8 equivalents
of the Fmoc-acid fluoride, 3 equivalents of DIEA and the resin in methylene chloride.
The couplings were allowed to reflux until an acceptable yield was determined by
2 37

quantitative Fmoc tests. '

After the first three residues were coupled to the resin, the

resin was placed on the Milligen 9050 synthesizer and the synthesis was continued.
Eight equivalents of preformed Fmoc-acid fluorides, three equivalents of DIEA and a 1.5
h recycling time were used for the couplings. A solution of 20% piperidine/2% 1,8diazobicyclo[4.5.0]undec-7-ene (DBU) in DMF was used for Fmoc removal.

The

peptides were simultaneously cleaved from the resin and side-chain deprotected using
reagent B (8.8:0.2:0.5:0.5, trifluoroacetic acid (TFA), triisipropylsilane,

water,

36

p h e n o l ) . T h e resulting solution was diluted with cold 30% acetic acid, washed with
diethyl ether (4 x 50 mL) and lyophilized.

The crude peptides were purified by

preparative reverse-phase HPLC on a Waters 15 pm Deltapak C4 column using a water
(0.05% TFA) and acetonitrile (0.05% TFA) gradient system. The gradient was run from
10% to 50% organic and the absorption was monitored at 222 nm. Peptide purity was
verified on a Vydac 5 pm C I8 column using the same conditions. Matrix assisted laser
desorption ionization (MALDI) mass spectrometry was used to verify peptide mass. Ich10 and Cyh-10 1276 (M+H)+.
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2.5.2 Amino Acid Analysis
Amino acid analyses were performed according to reference 2.21 using a
Beckman 6300 .Amino Acid Analyzer. In short, the peptides were hydrolyzed in 6N HC1
and 0.01% phenol for 24 h at 110°C. The samples were analyzed on a cation exchange
column at 65°C with post-column ninhydrin derivitization at 130°C.
2.5.3 MIC Assays
E. coli American type culture collection (ATCC) 25922 and S. aureus ATCC
25922 were used as representative Gram-positive and Gram-negative bacteria in the MIC
assays.

The bacterial cultures were grown in nutrient broth to midlog phase and

standardized using McFarland standard before dilution.

A 512 pg/mL peptide stock

solution was prepared and 1:2 serial dilutions were prepared and added to the culture
media to give final peptide concentrations of 256 pg/mL.
Fifty microliters of cells (5 X 104) and 50 pL of the peptide solution were added
to a sterile well and the MIC was determined by the lowest concentration that inhibited
cell growth. The inhibition of cell growth was indicated by the absence of turbidity after
four hours.

Turbidity in the wells was visualized manually.

The MIC values are

reported as the median value for at least three experiments.
2.5.4 In vivo B. Abortus Studies
Stock cultures of virulent B. abortus strain 2308 were passaged in BALB/c mice
and isolated in pure culture from spleens. Stock cultures were prepared from 48 hour
growth on Schaedler blood agar plates and stored at -80°C. For infections, the contents
were freshly thawed, pooled and diluted in sterile phosphate buffered saline (PBS) to a
concentration of 5x10s colony forming units (cfu) per mL.

Exact numbers were
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established by subsequent viable counts. Stock cultures for macrophage assays were
derived from the stocks above from a single solid passage.
Mice.

Female B ALB/c mice were purchased at 10 weeks of age from the

Department of Laboratory Animal Medicine at the LSU School of Veterinary Medicine
breeding colony. The animals were held 1 week prior to use.
Challenge infection of mice with B. abortus and peptide treatment Mice were
infected via the lateral tail vein with approximately 5xl04 cfu of B. abortus in 100 pL of
PBS. Approximately 4-6 weeks post infection, the mice were injected with a sublethal
dose of peptide and a control group was injected with diluent. After 24 h, the peptide
treatment group mice were sacrificed by C 0 2 asphyxiation and their spleens and livers
aseptically removed. The tissues were homogenized in 10 mL of PBS, serially diluted,
and plated in triplicate. Colonies were counted after 3 days of incubation at 37°C under
an atmosphere of 10% C 0 2.

Bacterial loads in the peptide treated animals were

compared to the diluent controls.
2.5.5 In Vitro Biological Studies
Preparation of cells. Modifications of the procedures described previously were
used to harvest and infect murine resident peritoneal macrophages with B. abortus-GFP
2 20 2

and M. chelonei. '

Following euthanasia, cells were harvested by lavage from the

peritoneal cavity of ten-week old BALB/c mice using 8 mL of DMEM (Dulbecco’s
Modified Eagle Medium) + 5% fetal calf serum (FCS). The cells were cultured in 96
well plates at a concentration of 1.5x10s per well in 200 pL of DMEM + 5% FCS at
37°C in 5% C 0 2. Cell cultures were enriched for macrophages by washing away non-

62

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

adherent cells after overnight incubation with PBS + 5% FCS and 200 pL of fresh media
was added to the cultures.
Determination of non-cytotoxic concentration of peptides. Normal macrophage
cultures were treated with 0 to 200 pM of the test peptide. The peptides were incubated
with the cells for 1 hour at 37°C in 5% C 0 2. The cells were washed 3 times with PBS +
5% FCS to remove any residual peptide. Peptide treated cells were stained with 0.04%
trypan blue in DMEM + 5% FCS. One to two hundred cells per well were counted using
an inverted microscope and the number of stained cells was recorded. Five wells were
examined per peptide concentration. Percent survival was calculated by subtracting the
number of blue (dead) cells from the total cells and normalized.
Infection of cells with B. abortus-GFP and M. chelonei. B. abortus-GFP or M.
chelonei opsonized with a sub-agglutinating dilution (1:2000) of hyperimmune BALB/c
mouse sera in DMEM + 5% FCS was added to the macrophages at a ratio of
approximately 100 bacteria per macrophage. Phagocytosis proceeded for 2 h at 37°C.
Extracellular organisms were removed by washing 3 times with PBS + 5% FCS and
fresh DMEM.
In vitro peptide treatment

Using non-cytotoxic concentrations, peptides were

added to infected and non-infected cell cultures for 1 hour at 37°C, 5% C 0 2. The cells
were washed 3 times with PBS + 5% FCS to remove any residual peptide. Percent
viability was determined as described above.
2.5.6

Statistical Analysis
A mean value for each spleen count was obtained by averaging the triplicate

values. Data was expressed as percent bacterial reduction compared to the appropriate
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controls. Percent bacterial reduction was determined by subtracting the total number of
organisms in the treated spleens from the total number of organisms in the control
spleens. This difference was divided by the total number of organisms in the control
spleens and multiplied by 100. Statistical comparisons between experimental groups
were performed using the two-tailed independent Student’s t test with p values less than
0.05 considered significant.
2.5.7

2 44

Biological Containment and Animal Use
All procedures involving live Brucellae and Mycobacteria were performed in a

Biological Level 3 (BL-3) containment facility at the LSU-SVM following Centers for
o 45

Disease Control/National Institutes of Health guidelines.”'

In conducting research

using animals, the investigators adhered to the “Guide for the Care and Use of
Laboratory Animals” prepared by the Committee on Care and Use of Laboratory
Animals of the Institute of Laboratory Animal Resources, National Research
„

.. 2.46
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Chapter 3
Structural Studies of Peptides Rich in a,a-Disubstituted Amino Acids
3.1 Introduction
The holy grail of de novo protein design is the ability to predict secondary
3 1-3 3

structure (i.e. a-helix, (3-sheet, or 310-helix) from the amino acid sequence. '

By far,

the a-helix is the most common and most studied secondary structure. Relatively little is
k n o w n about the facto rs favoring fo rm atio n o f th e 3 ^ -h e lix .3'4"3'8

T h e 3 10-helix

comprises approximately 10% of all helical structures and is thought to be a folding
3 5 3 9-3 13

intermediate to the a-helix. '

Small sections of 3i0-helices often occur in

g lo b u lar proteins an d a re thought to b e im p o rtan t in protein recognition.3'4’3' 15 Thus

efforts to study the 310-/a-helix equilibrium are important in increasing our knowledge of
the protein folding process.

Most studies exploring this equilibrium have been

concentrated on short, hydrophobic peptides containing several a,a-disubstituted amino
acids (aaA A 's).3' 16*3' 19 As a result, spectroscopic studies of these peptides have been
limited

to

organic

solvents

such

trifluoroethanol (TFE) and acetonitrile.

as

dimethylsulfoxide

(DMSO),

methanol,

Structures of these peptides have also been

3 20-3 23
o b tain ed by X -ray analysis o f crystals g ro w n fro m o rganic solvents. '
T h e a-h elix
3 24*3 26
h as been studied extensively in w ater a n d o rg an ic solvent system s. '

Recently,

Toniolo and co-workers have reported spectroscopic studies of a peptide exhibiting 3,03 27

helical structure in water. '

We have synthesized a series of amphipathic, water-
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soluble peptides comprised of 80% a a A A ’s. Here we report the helical structure of
these peptides using circular dichroism spectroscopy (CD).
3.2 Results
Each peptide was designed to form an amphipathic helix either in an a-helix or a
3,0-helix. The amphipathic helices have their charged residues along one side creating a
polar face and have their uncharged residues along the other side, creating a non-polar
face.

3 ^8 3 2 9

’

Pi-10 and Cyh-10 were designed to be perfectly amphipathic as an a -

helix while Ipi-10 and Ich-10 were designed to be perfectly amphipathic as a 3l0-helix.
Figures 3.1 to 3.4 show each peptide in its amphipathic helical form as well as it’s less
perfectly amphipathic alternative form. The large percentages o f a a A A ’s are used to
promote helicity. Amphipathy is used as the design tool to control which helix type is
formed. All peptides were synthesized and purified as previously reported.

3 30 3 31

In CD spectroscopy, helical peptides are characterized by two minima.

The

n-»7t’ transition is centered around 222 nm and the it—>n transition is centered near 207
3 32

nm. '

Since both the 310- and a-helices exhibit these minima, the intensities of the

minima are used to distinguish between these helical structures. The ratio, R, where R =
[0]n-wr>/[0]n-+jr* has been proposed as the factor to distinguish a 3i0-helix from an a helix. In 3t0-helices, R < 0.4 while for a-helices R = 1 3-32' 3-35 Tables 3.1 to 3.4 show
the % a-helicity and R for Pi-10, Cyh-10 and Ich-10 and the % 3i0-helicity and R for
Ipi-10 in various solvent systems. It was expected that the peptides would adopt the
helical structure that allowed them to be most amphipathic. In SDS micelles, all
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a-H elix
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Aib
Aib

Lys

Pi-10 H-Aib-Aib-Api-Lys-Aib-Aib-Api-Lys-Aib-Aib-NH g

Figure 3.1. Sequence and a - and 3I0-helical wheel diagrams of Pi-10.
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Figure 3.2. Sequence and a - and 310-helical wheel diagrams of Ipi-10.
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Figure 3.3. Sequence and a - and 3i0-helical wheel diagrams of Cyh-10.
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Figure 3.4. Sequence and a-helix and 310-helical wheel diagrams for Ich-10.
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Figure 3.5.

CD Spectra of Pi-10 (A), Ipi-10 ( ■ ) , Cyh-10 (♦ ) and Ich-10 ( • ) in SDS
micelles.
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Figure 3.6.

CD spectra of P i-10 in 1:1 CH3CN-H20 (▲), 9:1 CH3CN-H20 (♦), and
9:1 CH3C N -T F E (B ).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

20x10

15-

[6| (dec1 «■* i dmof')

10-

5 -

-5 -

-10-

180

190

200

210

220

230

240

250

Wavelength (nm)

F igure 3.7.

CD spectra of Ipi-10 in 1:1 CH3CN-H20 (▲), 9:1 CH3CN-H20 ( ♦), and
9:1 CH3C N -T F E (B ).
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Figure 3.8.

CD spectra of Cyh-10 in 1:1 CH3CN-H20 (A), 9:1 CH3CN-H20 (♦ ), and
9:1 CH3C N -T F E (» ).
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Figure 3.9.

CD spectra of Ich-10 in 1:1 CH3CN-H20 (▲), 9:1 CH3CN-H20 (♦), and
9:1 CH3C N -T F E (B ).
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Table 3.1
CD data and calculated structural information for Pi- 10.a
Solvent

[ e w bc

R

% Helicity

25 mM SDS

-8750

-7930

0.90

33 (a)

9:1 CHjCN-TFE

-10710

-7930

0.74

33 (a )

9:1 CH3CN-H20

-6180

-4290

0.71

22 (a )

1:1 CH3CN-H20
-3180
0.66
1 5 (a)
-2130
a Peptide concentration was 200 pM.
b Units for [0] are deg cm2 dm ol1.
c The minimum for the [©]*_>*• band is taken in the range from 205-209 nm.
d The minimum for the [©]„->*• band is taken in the range from 222-225 nm.

Table 3.2
CD data and calculated structural information for Ipi-10.a
Solvent

[ 0 W b’c

[ 0 W bd

R

% Helicity

25 mM SDS

-5520

-1750

0.32

25 (310)

9:1 CH3CN-TFE

-9920

-3150

0.33

33 (3 10)

9:1 CH3CN-H20

-6740

-3610

0.54

e

0.74
-4200
1:1 CH3CN-H20
1 9 (a)
-3120
a Peptide concentration was 200 pM.
b Units for [0] are deg cm2 d m ol1.
c The minimum for the [0]*-+** band is taken in the range from 205-209 nm.
d The minimum for the [0]„->if band is taken in the range from 222-225 nm.
c In this solvent, Ipi-10 is probably a mixture of coil structures. The % a-helix is
estimated to be 20% and the % 3i0-helix is estimated to be 31%.
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Table 3.3
CD data and calculated structural information for Cyh-10.a
[ e w bc

[ e ] „ ^ bd

R

% Helicity

25 mM SDS

-10870

-9980

0.92

39 (a)

9:1 CH3CN-TFE

-10290

-9010

0.88

3 7 (a )

9:1 CH3CN-H20

-9340

-8190

0.88

3 4 (a)

Solvent

1:1 CH3CN-H20
-7850
-7030
0.88
3 0 (a)
a Peptide concentration was 200 pM.
b Units for [0] are deg cm2 dmol'1.
c The minimum for the [9]*-,*. band is taken in the range from 205-209 nm.
d The minimum for the [0Jn_*,t. band is taken in the range from 222-225 nm.

Table 3.4
CD data and calculated structural information for Ich-10.a

[e W

[e]n_>Jc.bd

R

% Helicity

-4790

-5460

1.14

26 (a)

9:1 CH3CN-TFE

-10960

-8060

0.73

33 (a)

9:1 CH3CN-HzO

-6970

-6090

0.87

28 (a)

Solvent
25 mM SDS

1:1 CH3CN-HzO
0.97
2 9 (a )
-6770
-6580
a Peptide concentration was 200 pM.
b Units for [0] are deg cm2 dmol'1.
c The minimum for the [0]*-**. band is taken in the range from 205-209 nm.
d The minimum for the [0]n-«r« band is taken in the range from 222-225 nm.
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peptides, except Ipi-10, showed CD spectra characteristic of an a-helix (Figure 3.5). As
expected, P i-10 and Cyh-10 are a-helices in all solvent systems (Tables 3.1, 3.3 and
Figures 3.6, 3.8). Ipi-10 displays a transition from an a-helix to a 3 10-helix as the solvent
system increases in organic content (Table 3.2 and Figure 3.7). It was expected that Ich10 would display this same transition; however as can be seen in Table 3.4 and Figure
3.9, this did not occur.

Ich-10 displays an a-helical spectrum in all solvent systems

tested.
The percent a-helix was estimated according to the following: percent a-helix =
-lOO([0]Mir. + 3000)/33000, where the minimum for the [0]n_*R- transition is observed in
3 29

the range 222-225 nm. '
therefore,

we

have

Little work has been done to quantify the percent 3i0-helix;

used

the

CD

spectrum

of

H-(Leu-Arg-Leu)8-OH

in

diphosphatidylcholine liposomes as the model 3i0-helix. In this peptide, [0]„_>K.=-21,500
deg cm2 dmol'1 is defined as 100% 3i0-helix. '

Using this model, the above equation is

modified to estimate percent 3,0-helicity: percent 310-helix = - lOO([0]rc_,re./-2 1500).
3.3 Discussion
Factors stabilizing a-helices in many solvent systems have been extensively
3 36-3 38

studied. '

Coil to a-helix transitions have been observed as solvent systems
3 39

increase in organic content. '
35

helix/coil transitions. '

A similar observation is predicted to occur for 310-

One factor used to favor helices over a random coil is the

incorporation of helix promoting a a A A ’s. Usually, incorporation of more than 50%
3 16-3 23

aaA A ’s favors a 3i0-helix in short peptides. '

However, due to the lack of

81
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charged a a A A ’s, this factor has not been thoroughly studied as these studies have been
limited to organic media. With the advent of a convenient synthesis of the lysine-like
aaA A , Api, a polar aaA A can now be readily incorporated into peptides by solid-phase
techniques.

3 30 3 31 3 40
’ '

The use of this positively charged aaA A allows the

amphipathic design element to be extended to helical, water-soluble peptides. This will
allow CD studies to be performed on peptides in aqueous/organic solvent systems and
will allow us to probe the 3i0-/a-helix equilibrium in water, which is currently under
, . „ 3.5,3.9-3.12,3.27
debate.
In order to study the stability of the 3I0- and a-helices, one needs to be able to
distinguish between the two. It was thought that there was no difference in the CD
3 35
spectra for these two secondary structures. ‘
Other techniques such as electron spin
resonance and NMR are difficult and have met with mixed results, especially with
3 5-3 8 3 41
peptides containing aaA A ’s. ' '
'
Toniolo and co-workers have re-visited the
issue of using CD to resolve this issue. They conclude that the 3i0-helix has an R-value <
0.4 while the R-value for an a-helix is = 1. An additional distinguishing feature is the
positive CD band near 195 nm. This band is much weaker in the 310-helix than in the a helix. Toniolo shows that his CD spectra for 3i0-helices in phospholipid bilayers are in
agreement with that predicted by modeling.

3 32 3 33

All peptides tested contain 80% aaA A ’s to induce helicity. Pi-10 and Ipi-10
consisted of 6 Aib residues and 2 Api residues. Cyh-10 and Ich-10 consist of 6 Cyh
residues and 2 Api residues. The remaining amino acid residue ineach peptide is L82
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lysine. This natural amino acid is used to induce a right-handed helix, which will result
in a CD signal. The lack of this amino acid would result in no circular dichroism signal
as the peptide would have no preference for a right or left-handed helix. The L-lysines
are well seperated, near the middle of the sequence, to aid in the synthesis of the
..

peptides.

3.42, 3.43

In the peptides under study, amphipathy is the only factor used to influence the
formation of either a 3i0- or a-helix. P i-10 and Cyh-10 are designed to be a-helical
while Ipi-10 and Ich-10 are designed to be 3l0-helical. Each of these peptides is less
perfectly amphipathic in their alternative helix form (Figures 3.1 to 3.4) The peptides
showed minimal structure in water or pH 7.1-7.4, 2.5 mM phosphate buffer.

Upon

addition of 25 mM SDS micelles to P i-10, a transition to an a-helix spectrum with R =
0.90 and % a-helix = 33 % (Table 3.1 and Figure 3.5). The CD spectrum of Ipi-10 in 25
mM SDS micelles has an R = 0.32, indicative of a 310-helix (Table 3.2 and Figure 3.5).
The % 3i0-helicity is estimated to be 25%. As noted in other studies, the positive CD
3 32 3 34

band near 195 nm is weaker for Ipi-10 than for Pi-10. '

'

Cyh-10 displays a typical

a-helix CD spectrum in 25 mM SDS micelles with R = 0.92 and % a-helix = 39%
(Table 3.3 and Figure 3.5). Ich-10, which was expected to be a 3|0-helix, exhibits an a helical CD spectrum. The R-value for Ich-10 in SDS is 1.14 and % a-helix is 26%.
Though Ich-10 is perfectly amphipathic in a 3i0-helix, it nevertheless adopted an a-helix
structure. In the case o f Ich-10, its a-helix structure is not perfectly amphipathic but it is
still significandy amphipathic. In this form, the bulky cyclohexyl side chains on Cyh are
further apart than in a 3 io-helix. In a 3 10-helix, these side chains would be in proximity.
83
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CD spectra of all peptides in this study were taken in solvent systems ranging
from 100% organic to 1:1 organic/water (Tables 3.1 to 3.4 and Figures 3.6 to 3.8). Pi-10
and Cyh-10 are typical a-helices in each solvent.

Interestingly, P i-10 exhibits an

isodichroic point near 201 nm and Cyh-10, near 205 nm. This suggests a cooperative
helix/coil transition. An additional observation is the reduction of helicity as organic
solvent composition declines. The increase in helicity as the solvent system becomes
3 28

rich in organic composition has been observed in other monomeric a-helices. '

Others

have predicted that peptides with high percentages of a a A A ’s (> 50%), such as P i-10
3 20 3 42

and Cyh-10, would be 3l0-helical. '

In addition, theoretical calculations suggest

these peptides would exhibit a shift to a 3l0-helix as organic content increases.

35

This is

not observed in our studies, suggesting that amphipathy is a significant factor in
determining helix structure. Ipi-10 behaves as expected, displaying a weak a-helix in 1:1
CH3CN/H20 , 3i0-helical character in 9:1 CH3CN/H20 and stronger 3i0-helical character
in 9:1 CH3CN/TFE.

Ich-10 displays an a-helix structure in each solvent system.

Though still a-helical, the R-value for Ich-10 is lower in 100% organic solvent than the
other solvent systems.
The transition of Ipi-10 from an a-helix to a 3i0-helix and the lower R-value for
Ich-10 in 100% organic solvent agrees with predictions of solvent effects on the 310-/ahelix equilibrium. It has been shown that peptides rich in Aib favor a 3i0-helix in less
polar media and an a-helix in water. The increased stability of the 3 |0-helix in non-polar
solvents is due to the extra hydrogen bond formed relative to the a-helix. It is suspected
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that a-helices are favored in water because the “extra” carbonyl and amide are able to
hydrogen bond with the solvent.

35

For Pi-10, Cyh-10 and Ich-10, a maximum number of 7 hydrogen bonds are
possible in the a-helix conformation. For Ipi-10 in the 3i0-helical structure, 8 hydrogen
bonds are possible. Helix end effects and incomplete micelle binding tend to reduce the
3 29 3 44 3 45

absolute helicity of peptides..................

In the case of Pi-10, Cyh-10 and Ich-10, the

three N-terminal amides and the two C-terminal carbonyls do not have internal hydrogen
bonding partners.

For Ipi-10, the two N-terminal amides and the two C-terminal

carbonyls are without internal hydrogen bonding partners. As a result, the peptides may
3 46

adopt non-ideal structures at the ends to interact with solvent. '

Recently, Toniolo and

co-workers reported a short peptide exhibiting significant 3I0-helical structure in
3 27

water. '

The peptide contains the novel azacrowned functionalized amino acid, 2-

amino-3-[l-(l,4,7-triazacyclononane)] propionic acid.
As stated previously, a sufficient database of 3i0-helix structures does not yet
exist. As a result, estimation of % 310-helicity is difficult. It has been suggested that the
CD bands of a 3i0-helix will be highly dependent on the <|> and vjr torsion angles in the
peptide backbone. 3 I0-Helical peptides comprised of a a A A ’s have different 0 and y
angles than 3I0-helical peptides comprised only of natural amino acids.

3 20-3 23 3 32

Toniolo and co-workers synthesized Ac-(aMeVal)8-OtBu which exhibited significant
3 33 3 34

3i0-helical structure. '

Recently, Toniolo reported an additional short peptide
3 27

exhibiting 3i0-helical structure in water. '

Conflicting % 3 10-helix content can be
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calculated based on which peptide is considered to be a definitive 310-helix. Clearly,
more work needs to be done to resolve this issue.
3.4 Experimental
3.4.1 Peptide Synthesis
Cyh-10 and Ich-10 were synthesized as previously reported.

3 30 3 31

The first 3

residues were manually coupled onto PAL-PEG-PS solid support. The couplings were
done by gently refluxing 8 equivalents of the Fmoc-acid fluoride, 3 equivalents of DIEA
and the resin in methylene chloride. The couplings were allowed to gently reflux until an
acceptable yield was determined by quantitative Fmoc test.

3 47

After the first three

residues were coupled to the resin, the remainder of the peptide was synthesized using a
Milligen 9050 peptide synthesizer on the PAL-PEG-PS solid support using 8 equivalents
of preformed Fmoc-acid fluorides, 3 equivalents of DIEA and a 1.5 h recycling time.
Residues were double coupled when they were third in a series of a,a-disubstituted
amino acids.

A solution of 20% piperidine/2% l,8-diazabicyclo[4.5.0]undec-7-ene

(DBU) in DMF was used for Fmoc removal. The peptides were simultaneously cleaved
from the resin and side-chain deprotected using reagent B (8.8 : 0.2 : 0.5 : 0.5,
3 48

trifluoroacetic acid (TFA) : triisopropylsilane : water : phenol). '

The resulting acidic

solution was diluted with cold 30% acetic acid, washed with ethyl ether 94 x 50 mL),
and lyophilized. The crude peptides were purified by preparative reverse-phase HPLC
on a Waters 15 pM Deltapak C4 column using a water (0.05% TFA) and acetonitrile
(0.05% TFA) gradient system. The gradient was run from 10% to 50% organic and the
absorption monitored at 222 nm. Purity of the peptides was checked on a Vydac 5 pM
86
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C I8 column using the same conditions.

Matrix assisted laser desorption ionization

(MALDI) mass spectrometry was used to verify the peptide masses. Cyh-10 and Ich-10,
1276 (M+H)+.
3.4.2 C ircular Dichroism

Circular dichroism measurements were taken on a (+)-camphor sulfonic acid
calibrated Aviv 60DS spectrophotometer at 5°C. The measurements were recorded over
250-180 nm using a 0.1 cm pathlength quartz cell, 1 nm bandwith, 10 nm/min scan
speed and a 5 second time constant. Background spectra were acquired prior to each
sample spectrum and the two subtracted.

Three repetitive scans were recorded and

averaged to improve signal to noise. The reported mean residue ellipticity [0] (deg cm2
dmol'1) is derived from the observed ellipticity, [0]obs (millidegrees), using the formula
[0] = [0]Obs (MRW/10/c). MRW is the mean residue molecular weight of the peptide
(molecular weight of the peptide divided by the number of peptide bonds), I is the
pathlength (cm) and c is the peptide concentration (mg/mL).
Final peptide concentrations of 0.2 mM were used for all experiments.

The

peptides were dissolved in: trifluoroethanol for spectra taken in 9:1 CH3CN:TFE; pH
7.1-7.4, 2.5 mM phosphate buffer for spectra taken in SDS; and doubly distilled water
for the aqueous/organic spectra.

For representative aqueous/organic experiments, pH

7.1, 2.5 mM buffer was also used as the aqueous component and the resulting spectra
were nearly identical to the pure H20/C H 3CN spectra.
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Chapter 4
Synthesis of a Beta Sheet Prom oting Amino Acid
4.1 Introduction
Next to the a-helix. the most common and readily identifiable secondary structure in
4 1

proteins is the p-sheet. '

The basic unit of a P-sheet is the P-strand, a polypeptide that

is almost fully extended. This extended conformation is not particularly stable because
there are no favorable intra-strand interactions as are found in the a - and 3i0-helices.
The P-strand is stabilized when it is incorporated into a P-sheet, where hydrogen bonds
are formed between the peptide groups on adjacent strands. Adjacent strands can be
parallel or anti-parallel. Figures 4.1 and 4.2 show each of these structures. Anti-parallel
sheets are thought to be more stable than parallel sheets although this is not always the
case. Side chains from adjacent residues of the same strand protrude from opposite sides
of the sheet and do not interact with each other, but they can have significant interactions
with the side chains of neighboring strands.

4 1

The study of the P-sheet has recently gained interest due to the suspected
involvement of the P-sheet in diseases such as Alzheimer’s disease (AD), CreutzfeldtJacob disease (CJD) and bovine spongiform encephalopathy (mad cow disease). Despite
the fact that the P-sheet occurs almost as often as

the a-helix among secondary

structures found in proteins, relatively little is known about the factors that stabilize the
P-sheet.

The synthesis of small peptides to study the P-sheet structure has proven

elusive. Often, these peptides have a propensity to self-associate into large, generally
insoluble, quaternary P-sheet structures.

4 2 4 3

’

As a result, most recent studies have
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Figure 4.1. Parallel beta sheet.

Figure 4.2. Anti-parallel beta sheet.

focused on synthesizing a novel amino acid which serves as a (3-tum to nucleate P-sheet
formation. These P-sheet structures are intramolecular and are not a completely regular
structure because segments of the peptide that connect the strands (i.e. turns) must adopt
4 1 4 4 45

different conform ations...............

Therefore, it would be beneficial to assemble a (3-

sheet that is intermolecular. The strands are not covalently linked and would be free to
aggregate to form the P-sheet.

No alteration of conformation would be needed to

accommodate the amino acid making the turn. One problem with this approach is the
possibility of large-scale aggregation. Too many strands aggregating to form the p-sheet
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could lead to an insoluble protein. This problem could be avoided if the p-sheet could be
limited to a small number of strands, possibly as little as two strands.
A two-stranded P-sheet has two distinctly different amide hydrogen and a carbon hydrogen environments. The endo amide hydrogens, labeled Ha in Figure 4.3,
form an inter-strand hydrogen bond (H-bond) to complementary amide oxygens. The
endo a-carbon pro-R position, labeled Hb is sterically congested by a convergent Hb from
the anti-parallel strand. Therefore, only a proton is tolerated in that position. The exo
amide hydrogen, labeled He, lacks a specific complementary hydrogen bond partner and
could be replaced without disruption of the two-stranded P-sheet. Doig and co-workers
have replaced the Hc-like hydrogens of a three-stranded p-sheet with methyl groups,
46

thereby preventing further H-bond mediated oligomerization. '

Figure 4.3 also shows

that the exo a-carbon pro-R position, labeled Hd, is not sterically congested so this
position can also be substituted without disruption of the two-stranded P-sheet.
Replacement of He and Hj with cyclic tethers should stabilize two-stranded p-sheet
model systems as shown in Figure 4.4.
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Figure 4.3. Two stranded beta sheet with exo and endo positions shown.
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Most de novo (3-sheet models use natural or artificial (3-tums or linkers to initiate
4 6-4 12

intramolecular p-sheet dimers. '

By incorporating lactam-constrained amino acids

as well as a-amino acids, it should be possible to synthesize a peptide that is pre
organized to have extended-like conformations.

Unlike the hairpin model systems

discussed above, these individual extended conformation strands should spontaneously
self-assemble into p-sheet dimers when a minimum peptide length is reached. T he use
of lactam-constrained amino acids, like Doig’s approach, should inhibit further H-bond
mediated oligomerization because the amide Hc atoms are replaced.
In order to determine the correct tether for the lactam-constrained amino acid,
selected distances in several peptides having protons in Hc- and Hd-Iike environments
were measured using Sybyl. The average distance between He and Hd is 2.25 A . Plane
angles were then calculated from the HN-amide and pro-R a-CH-carbonyl. The relative
plane angle differences were between 12° to 20°. The ith C-Hd and /th + 1 H-Nc are held
close to parallel to each other in the extended conformation. The distance between the
ith C-H<i and /th + 1 N-Hc bonds is almost perfectly spanned by a 3-carbon tether,
resulting in a six-membered lactam-constrained dipeptide (Figure 4.5).
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H
OH

Figure 4.5. Six-membered lactam-constrained dipeptide amino acid.
It is important to note the replacement of the pro-/? Hd position with a 3-carbon
tether requires the D-amino acid configuration. Pro-5 amino acid side chains alternate
pointing up and down in the /th +1 and ith constrained lactam amino acids in Figure 4.4.
In the proposed model, the hydrogen is pointing down in the /th pro-5 amino acid
position and pseudo axial on the six-membered lactam. The sterically larger amino
group occupies a pseudo equatorial position on the six-membered lactam.

This

configuration should favor the extended conformation in peptides incorporating the
proposed constrained lactam amino acid.
The control of conformation with six-membered rings is well documented. The
earliest known synthesis of a lactam-constrained amino acid was reported by Freidinger
4 13

and co-workers. ‘

He reports the synthesis of a glycine-like six-membered lactam-

constrained dipepdde derivative (Figure 4.6A). Others have since worked to synthesize
4 14-4 18

similar lactam-constrained dipeptide amino acids for study. '

Zydowsky and co-

workers synthesized glycine- and phenylalanine-like lactam-constrained dipepdde amino
acids that were a,a-disubstituted at the a-carbon of the lactam (Figure 4.6B). They
further report modest coupling yields of the amino acids (68-92%) in the synthesis of a
4 19

peptide dimer. '

Moss and co-workers report the synthesis o f a ureido-based
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peptidomimetic inhibitor of a herpes simplex virus enzyme. Their inhibitor contains a
lactam-constrained dipepdde amino acid.

However, the synthesis of the lactam-

constrained dipepdde amino acid involves a lengthy and expensive procedure to obtain
4 20

an aldehyde intermediate. '

Here we report an improved route to a novel lactam-

constrained amino acid that is incorporated, in high yields, in a peptide pre-designed to
form a P-sheet dimer.

, co 2h

, co 2h

H2N

if "

Ph
R = methyl or methylphenyl

B

Figure 4.6. Freidinger (a) and Zydowsky (b) constrained lactam amino acids.
4.2 R esults and Discussion
The general structure of the target amino acid is shown in Figure 4.5. The amino
acid is constructed from a six-membered ring backbone previously shown to promote an
4 13

extended conformation. '

Specifically, we sought to synthesize the valine derivative of

a constrained dipeptide amino acid (Figure 4.7) because valine is known to promote the
4 21-4 23

P-sheet structure. ‘

The valine moiety is introduced via a reductive amination.

The reductive amination step is likely adaptable to constrained dipeptide amino acids.
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Figure 4.7. Target constrained dipeptide amino acid.
The key to the synthesis of the constrained dipepdde amino acid unit (DPU) is
the synthesis of an a-amino acid semialdehyde. The synthesis of the aldehyde is based
4 24

on a synthetic route developed by Martin and co-workers. '

Figure 4.8 outlines the

steps involved in the aldehyde synthesis. The synthesis begins with the esterification of
D-glutamic acid, 4.1, with dry allyl alcohol, under argon, in the presence of
trimethylsilylchloride (TMS-C1, 4.4 equivalents) to yield the diester after 3 days.
Triethylamine (6.5 equivalents) and Boc anhydride (1.1 equivalents) were added
sequentially and the reaction mixture was stirred overnight. Removal of the allyl alcohol
followed by trituration with diethyl ether and filtration through a celite pad gave
compound 4.2 in quantitative yield. The presence of the product was verified by FABMS (328, M+H*). In addition, 'H NMR and l3C NMR verified the presence of the Boc
and allyl groups by appearance of t-butyl and allyl protons and carbons, respectively.
This reaction is versatile in that the scale can be varied greatly (1 gram to 15 grams) with
little effect on purity or yield.
The a-nitrogen in 4.2 is still quite nucleophilic, especially towards an aldehyde.

4 20

As a result, the nitrogen must be doubly protected prior to introduction of the aldehyde.
A simple way to achieve this protection is to introduce another Boc group. Compound
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4.2 is dissolved in dry acetonitrile along with N, N-dimethylaminopyridine (DMAP, 0.2
equivalents) followed by Boc anhydride (1.1 equivalents). After two hours, an additional
0.2 equivalents of DMAP and 0.5 equivalents of Boc anhydride are added. The red
solution is allowed to stir overnight, after which the solvent is removed. The residue is
taken up in a minimum volume of hexanes/ethyl acetate (7:3) and is purified via flash
column chromatography over silica gel to give 4.3 in 95% yield. The presence of the
product was verified by FAB-MS (428, M+FP). The product was also verified by a
slight change in the chemical shift of the protons and carbons in the Boc group as
determined by 'H and l3C NMR.
With the fully protected D-glutamic acid, the key aldehyde intermediate can be
synthesized. Compound 4.3 is dissolved in dry diethyl ether under argon. Diisobutyl
aluminum hydride (DIBAL, 1.0M solution in hexanes, 1.5 equivalents) is added drop
wise at -78° C. The reaction is stirred at -78° C for 30 minutes at which time it is
quenched with methanol and 10% sodium bisulfate. After extraction with 10% sodium
bisulfate, the organic layer is dried and evaporated to give 4.4 in 98% yield.

The

presence of the product was verified by FAB-MS (372, M+H+). The product was further
verified by the disappearance of one group of allyl protons and carbons and the
appearance of the characteristic aldehyde proton and carbon as shown in ‘H and l3C
NMR.
It should be noted that the selective reduction of only the side-chain ester is vital to the
success of this synthetic scheme. DIBAL is a common reagent used in the reduction of
esters to aldehydes. Martin and co-workers reported the selective reduction of the sidechain methyl ester over the mam chain ester.

4 24

However, great care had to be taken to
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limit the reaction time to 5 minutes so as not to reduce the main chain ester as well. In
addition, the temperature must be kept at -78° C or over reduction to the alcohol will
4 24

result. ‘

The stability of the aluminum-oxygen complex at this temperature is the key

in the reduction to the aldehyde. Premature release of the aldehyde as a result of the
collapse of the aluminum-oxygen complex will result in reduction to the alcohol in the
presence of hydride. Initially, we sought to repeat Martin’s technique by synthesizing
the fully protected dimethyl ester of D-glutamic acid.

The synthesis was easily

accomplished and variations in the conditions of the selective ester reduction confirmed
its extreme sensitivity towards over reduction.

We encountered difficulties in

hydrolyzing the methyl ester, the next step in our synthetic scheme to the DPU. At this
point, we decided to make the diallyl ester instead. The selective reduction was carried
out as before and we were pleasantly surprised to discover that it was much more robust
than previously observed. The reduction time can be extended and the temperature
can be varied without any apparent over reduction. We believe the allyl ester provides
additional steric hindrance on the main chain ester resulting in exclusive attack of the
DIBAL on the side- chain ester.
With the fully protected semi-aldehyde in hand, the synthetic route of the
constrained dipeptide amino acid can be altered to accommodate virtually any amino
4 25

acid via reductive amination. '

In our case, we chose to use L-valine to continue the

synthesis (Figure 4.9). Compound 4.4 and L-Val-OtBu-HCl (1 equivalent) were stirred
in dry 1,2-dichloroethane (DCE).

Triethylamine (TEA, 1.1 equivalents) was added

followed by sodium triacetoxyborohydride (1.4 equivalents). The solution was stirred
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Figure 4.8. Synthetic route to the key aldehyde intermediate.

100

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

overnight, after which it was washed with saturated sodium bicarbonate. The organic
layer was dried and evaporated to provide 4.5 in 90% yield. The presence o f the product
was verified by FAB-MS (529, M+H*)- In addition, *H and 13C revealed the presence of
the valine side-chain methyl groups as well as the t-butyl ester.
Cyclization of 4.5 will yield the constrained dipeptide amino acid.

In order to

accomplish this step, the allyl ester must be removed. Acid hydrolysis of the ester is not
prudent, as the t-butyl ester on the valine moiety will also be removed. Base hydrolysis
proved to be too slow to be feasible. A logical alternative is the palladium-catalyzed
removal of allyl groups.4' ^ ’ 4‘^
(DCM) under argon.

Compound 4.5 is dissolved in dry dichloromethane

Morpholine (10 equivalents) is added, followed by palladium

tetrakistriphenylphosphine (0.1 equivalents). After 30 minutes, the reaction mixture is
washed with IN hydrochloric acid and the organic solvent is dried and removed. The
crude product is taken up in ethanol/DCM (9:1) and purified by flash column
chromatography to give 4.6 in 85% yield. The presence of the product is verified by
FAB-MS (490, M+FT)- Further evidence of the removal of the allyl ester is provided by
the absence of the allyl protons and carbons as shown in ‘H and 13C NMR spectra of the
product.
Compound 4.6 can be cyclized to the constrained dipeptide amino acid by an
intramolecular amide bond formation. Compound 4.6 is dissolved in dry acetonitrile to
which is added HATU (1 equivalent) and diisopropylethylamine (DIEA, 2.1
equivalents). After stirring for 2 hours, the solvent is removed, the residue taken up in
DCM and washed with 10% sodium bisulfate. The DCM is dried and evaporated to
yield 77% of cyclized product, 4.7. The presence of the product is verified by FAB-MS
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(472, M+H*) as well as an X-ray crystal structure of the product (Figure 4.10). Tables
4.1 to 4.3 give the bond distances, bond angles and torsion angles, respectively for 4.7.
The

angle in 4.7 is 150.3°, which compares favorably to the ideal angle of 135° in an

antiparallel P-sheet.
The Boc protecting groups and t-butyl ester must be removed in order to prepare
the DPU for coupling. This is easily accomplished by treating 4.7 with approximately 5
mL of DCM/TFA (1:1) for 15 minutes. The DCM/TFA mixture is then removed under
vacuum. To prepare the amino acid for coupling, the a-nitrogen must be protected. A
convenient protecting group is the Fmoc group.

Two routes have been utilized to

introduce this protecting group. Figure 4.11 shows both synthetic routes. The first is a
4 28

method used by Lapatsanis and co-workers. '

In this method, the residue is taken up

in sufficient 9% sodium carbonate to give a solution with pH 9. The reaction mixture is
cooled to 0° C and a solution of Fmoc-OSu (1.05 equivalents) in dioxane is added. After
stirring for 2 hours, the reaction mixture is diluted with water and extracted with diethyl
ether followed by ethyl acetate. The aqueous phase is cooled in an ice bath and acidified
to pH 2 with concentrated hydrochloric acid.

The Fmoc-protected amino acid is

extracted with ethyl acetate, which is then dried and evaporated. The crude product is
purified by flash column chromatography to give 4.8 in 51% yield. The presence of the
product is verified by FAB-MS (437, M+H*). Proton and carbon NMR spectra verify
the removal of the Boc groups and the t-butyl ester. The Fmoc protecting group is
verified by the appearance of aromatic hydrogens and carbons in the respective spectra.
An alternative procedure to introduce the Fmoc protecting group was developed by Bolin
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4 29

and co-workers. ’

suspended in DCM.

The residue from the Boc-group and t-butyl ester removal is
TMS-C1 (2.5 equivalents) is added to the ice cooled reaction

mixture followed by DIEA (3.0 equivalents) and Fmoc-CI (1.1 equivalents).

This

procedure is convenient as it solubilizes the amino acid by neutralizing the free amino
function with DDEA and forms the silyl ester with TMS-C1 in neat organic media. The
neutral, organic-soluble amino acid is reacted with Fmoc-CI to yield the protected
amino acid. The product is purified via silica gel chromatography to give 4.8 in 85%
yield.
With the fully protected constrained lactam amino acid in hand, a peptide designed
to prefer an extended conformation can now be synthesized. The peptide under study,
Ac-Lys-Lys-Lys-DPU-DPU-Lys-Lys-NH2, was assembled using a Milligen 9050 peptide
synthesizer on PAL-PEG-PS solid support.

The couplings were done in N, N-

dimethylformamide (DMF) using a four-fold excess of the Fmoc-amino acids, three
equivalents of DIEA, four equivalents of HATU and a one-hour recycling time. Fmoc
removal

was

accomplished

by

treatment

with

a

solution

diazobicyclo[4.5.0]undec-7-ene (DBU), 20% piperidine in DMF.

of

2%

1,8-

Acetylation of the

peptide was carried out by treating the resin bound peptide with a 0.2M solution of acetic
anhydride in 0.28M DIEA solution in DMF for 40 minutes.

Side-chain and resin

cleavage was done by treatment with TFA, triisopropylsilane,
4 30

(8.8:0.2:0.5:0.5) (reagent B) for 2 hours. '

water, phenol

The peptide was purified by preparative

reverse-phase HPLC on a C4 column using a gradient of water and acetonitrile with
0.05% TFA in each. Molecular weight and amino acid composition were verified by
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Figure 4.9. Synthetic route to Boc-protected constrained lactam amino acid.
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Table 4.1
Bond distances (A) for 4.7.a

Atom 1

A tom 2

D istance

Atom 1

A tom 2

D istance

Ol

Cl

1.213(2)

Cl

C2

1.522(2)

02

CIO

1.317(3)

C2

C3

1.527(3)

02

C ll

1.484(3)

C3

C4

1.504(4)

03

CIO

1.201(3)

C4

C5

1.499(3)

04

C15

1.319(3)

C6

Cl

1.534(5)

04

C16

1.470(3)

C6

C20

1.526(4)

05

C15

1.201(3)

C7

C8

1.523(4)

06

C20

1.324(4)

Cl

C9

1.528(5)

06

C21

1.480(6)

C ll

C12

1.519(5)

07

C20

1.189(4)

C ll

C13

1.468(4)

N1

Cl

1.361(3)

C ll

C14

1.511(4)

N1

C5

1.471(3)

C16

C17

1.506(5)

N1

C6

1.453(2)

C16

C18

1.497(5)

N2

C2

1.463(3)

C16

C19

1.513(4)

N2

CIO

1.404(3)

C21

C22

1.510(1)

N2

C15

1.389(3)

C21

C23

1.563(6)

aNumbers in parentheses are estimated standard deviations in the last digits.
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Table 4.2
Bond angles (°) for 4.7 .a

Atom 1

A tom 2

Atom 3

Angle

A tom 1

Atom 2

Atom 3

Angle

CIO

02

C ll

121.3(2)

C6

Cl

C9

111.4(2)

C15

04

C16

121.6(2)

C8

Cl

C9

127.1(2)

C20

06

C21

123.8(3)

02

CIO

03

127.1(2)

Cl

Nl

C5

123.9(2)

02

CIO

N2

111.6(2)

Cl

N1

C6

118.7(2)

03

CIO

N2

121.2(2)

C5

Nl

C6

117.0(2)

02

C ll

C12

102.4(2)

C2

N2

CIO

115.9(2)

02

C ll

C13

111.1(2)

C2

N2

C15

117.2(2)

02

C ll

C14

108.9(2)

CIO

N2

C15

126.8(2)

C12

C ll

C13

111.3(3)

Ol

Cl

Nl

122.3(2)

C12

C ll

C14

110.3(2)

Ol

Cl

C2

120.2(2)

C13

C ll

C14

112.3(3)

N1

Cl

C2

117.3(2)

04

C15

05

126.3(2)

“Numbers in parentheses are estimated standard deviations in the last digits.
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Table 4.2 (cont’d)

A tom I

Atom 2

A tom 3

Angle

A tom 1

Atom 2

A tom 3

Angle

N2

C2

Cl

109.7(2)

04

C15

N2

111.6(2)

N2

C2

C3

113.0(2)

05

C15

N2

121.9(2)

C2

C3

C4

109.9(2)

04

C16

C18

102.2(2)

C3

C4

C5

108.6(2)

04

C16

C19

108.6(2)

Nl

C5

C4

113.8(2)

C17

C16

C18

113.2(2)

Nl

C6

Cl

114.0(2)

C17

C16

C19

109.8(3)

Nl

C6

C20

108.0(2)

C18

C16

C19

111.3(3)

Cl

C6

C20

112.6(2)

06

C20

07

124.7(3)

C6

Cl

C8

110.5(3)

06

C20

C6

110.4(3)

07

C20

C6

124.8(3)

06

C21

C23

106.4(5)

06

C21

C22

99.0(5)

C22

C21

C23

107.0(5)
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Table 4 3
Torsion angles (°) for 4.7.a

Atom 1

A tom 2

Atom 3

Atom 4

Angle

C ll

02

CIO

03

1.28(0.33)

C ll

02

CIO

N2

-175.31(0.17)

CIO

02

C ll

C12

178.42(0.21)

CIO

02

C ll

C13

-62.62(0.31)

CIO

02

C ll

C14

61.57(0.27)

C16

04

C15

05

-8.58(0.31)

C16

04

C15

N2

175.24(0.17)

C15

04

C16

C17

58.21(0.29)

C15

04

C16

C18

179.37(0.23)

C15

04

C16

C19

-62.93(0.29)

C21

06

C20

07

4.48(0.57)

C21

06

C20

C6

-174.12(0.33)

C20

06

C21

C22

-171.81(0.48)

C20

06

C21

C23

-60.97(0.57)

C20

06

C21

C24

64.13(0.58)

C5

N1

Cl

Ol

172.66(0.21)

C5

N1

Cl

C2

-11.78(0.32)

C6

N1

Cl

Ol

0.36(0.33)

aNumbers in parentheses are estimated standard deviations in the last digits.
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Table 4.3 (cont’d)

Atom 1

Atom 2

Atom 3

Atom 4

Angle

C6

N1

Cl

C2

175.92(0.21)

Cl

N1

C5

C4

27.59(0.33)

C6

N1

C5

C4

-159.99(0.23)

Cl

N1

C6

C7

106.98(0.24)

Cl

N1

C6

C20

-127.04(0.23)

C5

N1

C6

Cl

-65.85(0.27)

C5

N1

C6

C20

60.13(0.30)

CIO

N2

C2

Cl

-47.58(0.23)

CIO

N2

C2

C3

82.25(0.22)

C15

N2

C2

Cl

131.26(0.18)

C15

N2

C2

C3

-98.91(0.22)

C2

N2

CIO

02

151.48(0.17)

C2

N2

CIO

03

-25.34(0.28)

C15

N2

CIO

02

-27.23(0.27)

C15

N2

CIO

03

155.94(0.20)

C2

N2

C15

04

156.79(0.16)

C2

N2

C15

05

-19.58

CIO

N2

C15

04

-24.51(0.26)
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Table 4.3 (cont’d)

Atom 1

A tom 2

Atom 3

A tom 4

Angle

CIO

N2

C15

05

159.12(0.19)

Ol

Cl

C2

N2

-34.09(0.27)

Ol

Cl

C2

C3

-162.77(0.20)

N1

Cl

C2

N2

150.25(0.19)

N1

Cl

C2

C3

21.57(0.29)

N2

C2

C3

C4

-173.99(0.20)

Cl

C2

C3

C4

-46.94(0.28)

C2

C3

C4

C5

61.24(0.28)

C3

C4

C5

Nl

-51.48(0.29)

N1

C6

Cl

C8

-169.13(0.22)

N1

C6

Cl

C9

-46.98(0.26)

C20

C6

Cl

C8

67.32(0.29)

C20

C6

Cl

C9

-170.52(0.22)

N1

C6

C20

06

58.24(0.31)

N1

C6

C20

06

-120.36(0.33)

Cl

C6

C20

06

-174.93(0.24)

Cl

C6

C20

07

6.47(0.41)
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Procedure 1:
1) TFA/DCM (1:1)
2) Na2C 03
3) Fmoc-OSu. Dioxane
OtBu

Procedure 2:
1) TFA/DCM (1:1)

FmocN

2) TMS-C1. DIEA.
Fmoc-Q
4.7

4.8

Figure 4.11. Synthetic routes to Fmoc protecting group introduction.

MALDI mass spectrometry and amino acid analysis, respectively. Figures 4.12 to 4.14
are representative examples of crude analytical and

preparative scale HPLC

chromatograms. Figure 4.15 shows the chromatogram of the purified peptide run on a
C18 column.

It should be noted that throughout the HPLC process, multiple peaks

containing exact masses were obtained. We believe that this is indicative of peptide
aggregation on the HPLC columns. Figures 4.16 and 4.17 show MALDI mass spectra of
the crude and pure peptide, respectively.
Once the peptide was purified, circular dichroism spectroscopy was used to determine
which secondary structure, if any, was present. Specifically, we were looking for a (3112
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sheet structure. (3-Sheet peptides exhibit a minimum near 217 nm and a maximum near
195 nm representing n—»re* and iz—>n transitions, respectively.

CD spectra were

acquired in a variety of solvent conditions: 100% trifluoroethanol and 7mM phosphate
buffer (at several pH’s) to determine the solvent effect on secondary structure.

In

addition, the concentration of the peptide was varied from 50 pM to nearly 300 mM to
see if there was a concentration dependence on structure. Representative CD spectra are
shown in Figure 4.18. At relatively low peptide concentrations (50 to 500 pM), the
peptide adopted a random coil conformation, regardless of solvent, pH or peptide
concentration (Figures 4.20 and 4.21). In a random coil, a peptide exhibits a minimum
near 197 nm (re—»re*) and a maximum near 217 nm (n—»re*). At relatively high peptide
concentrations, no useful CD spectra were obtained; however, as the peptide
concentration was lowered, a return to a random coil spectrum was observed (Figure
4.19). Clearly, a (3-sheet dimer was not obtained using this peptide. It is possible that
the large number of lysine residues relative to the number of DPU residues could disrupt
the dimer formation due to the positive charge on the side-chain amino groups.
However, when the pH was adjusted above the pKa of these amino groups, no observable
shift to a (3-sheet structure was observed.

Another possibility is that the minimum

number of DPU residues needed to nucleate (3-sheet dimer formation has not been
reached.

If this were the case, other peptides would need to be synthesized, with

increasing numbers of DPU residues, until the P-sheet dimer is observed. An interim
solution would be to synthesize a small peptide that incorporates a P-tum. This would
result in the formation of an intramolecular dimer rather than the desired intermolecular
dimer, but it would provide useful information to characterize the p-sheet dimer.
113
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Figure 4.12.
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Analytical scale HPLC chromatogram of crude target peptide
prior to ether wash.
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Figure 4.13. Analytical scale HPLC chromatogram of crude target peptide.
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80.00

Figure 4.14. Preparative scale HPLC chromatogram of crude target peptide.
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Figure 4.15. Analytical scale HPLC chromatogram of pure target peptide.
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Figure 4.16. MALDI mass spectrum of crude target peptide.
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Figure 4.17. MALDI mass spectrum of pure target peptide.
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Figure 4.18.

190

200

210
220
Wavelength (nm)

230

240

250

CD spectra of target peptide (200pM) in TFE (•), pH 7 phosphate buffer
(■), pH 10 phosphate buffer (A ) and pH 10.5 phosphate buffer (♦).
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180

Figure 4.19.
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CD spectra of target peptide in water at 280mM (• ) , 140mM (■),
50mM (A ), 25mM (▼), 12mM (♦), 6 mM (o), 3mM (□).
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Figure 4.20.
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CD spectra of target peptide in TFE at 595pM (A ), 297pM (■), 200pM
(•)■

118

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

[6 ] (deg x cm2 x dmoT1)

-5 -

-

10-

-15x10
180

Figure 4.21.
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CD spectra of target peptide in pH 10.5 phosphate buffer at 400pM (♦),
350pM (▼), 300pM (▲), 250pM (■), 200pM (•).
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4.3 Experimental
o
HN

OH

1) TMS-C!
A lly l a lc o h o l

OH

4.1

4.3.1

4 .2

diallyl (R)-2-/erf-butoxycarbonylaminopentanedioate (4.2)

To an ice cold stirred suspension of D-glutamic acid (4.1) in dry allyl alcohol
(150 mL) was slowly added TMS-C1 (17.3 mL, 136 mmol, 4.4 equiv.).

After the

addition was completed, the ice bath was removed and the reaction was stirred at room
temperature for three days. Triethylamine (31 mL, 221 mmol, 6.5 equiv.) and Boc20
(8.2 g, 37.4 mmol, 1.1 equiv.) were added sequentially and the reaction mixture was
stirred overnight.

The solvent was removed under reduced pressure, the residue

triturated with ethyl ether and filtered through a Celite pad. The solvent was evaporated
yielding a yellow oil as the pure product (11.1 g, 100%). 'H NMR (250 MHz, CDC13) 8
1.43 (s, 9H), 1.99 (m, 2H), 2.19 (m, 2H), 2.47 (m, 1H), 4.58 (d, 2H), 4.63 (d, 2H), 5.29
(m, 4H), 5.55 (d, 1H), 5.90 (m, 1H), 5.92 (m, 1H). l3C NMR (62.5 MHz, CDC13) 5
27.19, 28.03, 30.01, 52.76, 64.95, 65.58, 79.41, 117.92, 118.38, 131.48, 131.94, 155.24,
171.66, 172.03. FAB-MS 328 (M+H)+.
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B o cN

4 Jl

4.3.2

43

diallyl (2R)-2-Ar-[bis (terf-butyDoxycarbonyi]amino}-pentanedioate (4.3)
To a stirred solution of 4.2 (5 g, 15.3 mmol) and DMAP (379 mg, 3.1 mmol, 0.2

equiv.) in dry acetonitrile (50 mL) was added Boc20 (3.67 g, 16.8 mmol, 1.1 equiv.) at
room temperature. After two hours, an additional 1.35 g Boc20 and 379 mg DMAP
were added and the red solution was allowed to stir overnight. The solvent was removed
under reduced pressure and the residue taken up in hexanes/ethyl acetate (7:3). The
crude product was purified by flash column chromatography to yield the pure product,
4.3, as a yellow oil (6.17 g, 95%). 'H NMR (250 MHz, CDC13) 6 1.49 (s, 18H), 2.20 (m,
2H), 2.45 (t, 1H), 2.50 (m, 2H), 4.58 (d, 2H), 4.61 (d, 2H), 5.28 (m, 4H), 5.88 (m, 1H),
5.93 (m, 1H). ,3C NMR (62.5 MHz, CDC13) 8 25.05, 28.08, 30.86, 57.52, 65.34, 65.88,
83.43, 118.27, 118.33, 131.86, 132.31, 152.11, 170.15, 172.44. FAB-MS 428 (M+H)+.
Anal, calcd for C2,H 33N 0 8: C, 59.02; H, 7.73; N, 3.28. Found: C, 59.18; H, 7.70; N,
3.45.
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(B o c )2N

DIBAL

Et->0. -78° C
H

43

4.3.3

4.4

allyl (2R)-2-Ar-[bis (/irf-butyl)oxycarbonyl]-ainino}-5-oxopentanoate (4.4)
A solution of 4.3 (1 g, 2.34 mmol) in dry EtzO was cooled to -78° C. DEBAL

(3.51 mL, 1.0M in hexanes, 3.51 mmol, 1.5 equiv.) was slowly added over 10 minutes.
The reaction was stirred for 30 minutes after the addition was completed and quenched
with methanol (4 mL) and 10% NaHS0 4 (2mL).

The mixture was stirred at room

temperature for 30 minutes then extracted with 10% N aH S0 4 and the solvent evaporated
to yield the product, 4.4, as a yellow oil (0.84 g, 98%). 'H NMR (200 MHz, CDC13) 5
1.49 (s, 18H), 2.18 (m, 2H), 2.54 (m, 2H), 2.56 (t, 1H), 4.62 (m, 2H), 4.91 (m, 1H), 5.27
(m, 2H), 9.78 (t, 1H). 13C NMR (50 MHz, CDC13) 5 22.45, 28.09, 40.61, 57.55, 65.93,
83.57, 118.34, 131.84, 152.16, 170.07,201.01. FAB-MS 372 (M+H)*'.
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o

TEA, DCE

HN

H

A
4.4

4.3.4

4.5

tert- butyl
(2S)-2-/V-1-[(5-ally lcarboxy la te)-(4R)-bis(JV',
butyloxycarbonylamino)pentyl]-2-amino-3-methyl-butanoate (4.5)

N'-tert-

Compound 4.4 (2 g, 5.39 mmol) and L-valine-OtBu (1.13 g, 5.39 mmol, 1 equiv.)
were dissolved in dry DCE (100 mL) under argon. TEA (0.83 m L 5.93 mmol, 1.1
equiv.) was added followed by sodium triacetoxyborohydride (0.97 g, 7.55 mmol, 1.4
equiv.). The mixture was stirred overnight then washed with saturated N aH C 0 3 (3 x 50
mL). The organic layer was dried over Na 2S 0 4 and evaporated. The residue was taken
up in hexanesrethyl acetate (4:1) and purified by flash column chromatography to yield
4.5, a yellow oil (2.56 g, 90%). lH NMR (250 MHz, CDC13) 5 0.92 (d, 6 H), 1.47 (s,
9H), 1.49 (s, 18H), 2.10 (m, 7H), 2.45 (t, 1H), 2.80 (d, 1H), 4.60 (d, 2H), 4.62 (m, 1H),
5.27 (m, 2H), 5.90 (m, 1H). I3C NMR (62.5 MHz, CDC13) 8 18.92, 19.31, 27.21, 27.56,
28.13, 28.33, 31.84, 48.25, 58.29, 65.72, 68.08, 80.86, 83.11, 119.09, 132.03, 152.31,
170.71, 174.82. FAB-MS 529 (M+H)*. Anal, calcd for C 27H48N20 8: C, 59.34; H, 9.16;
N, 5.13. Found: C, 59.34, H, 8.76; N, 5.05.
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(B ocfcN

OH
Pd(PPh3)4
M o r p h o li n e

DCM
HN

HN

/

4.6

4.5

4.3.5

\

N'-tertferT-butyl
(2S)-2-JV-l-[(5-carboxy)-(4R)-bis(iV;
butyloxycarbonylamino) pentyl]-2-amino-3-methyl-butanoate (4.6)
Compound 4.5 (1.77 g, 3.35 mmol) was dissolved in dry DCM (30 mL) under

argon. Morpholine (2.92 mL, 33.5 mmol, 10 equiv.) was added followed by Pd(PPh 3)4
(0.42 g, 0.335 mmol, 0.1 equiv.). The solution was stirred for 30 minutes and then was
washed with IN HC1 (2 x 50 mL).

A precipitate formed which was kept with the

organic layer. The organic layer is dried over Na2S 0 4 and evaporated to yield a yellow
residue. The residue is taken up in CHCl3:MeOH (9:1) and purified by flash column
chromatography to yield 4.6, a yellow oil (1.39 g, 85%). 'H NMR (250 MHz, CDC13) 5
0.98 (m, 6 H), 1.47 (s, 9H), 1.48 (s, 18H), 1.62 (m, 1H), 2.18 (m, 6 H), 2.66 (m, 2H), 3.12
(d, 1H), 4.66 (m, 1H).

,3C NMR (62.5 MHz, CDC13) 5 18.27, 19.56, 26.37, 28.22,

28.34, 28.49, 30.93, 47.74, 50.92, 59.28, 66.96, 82.24, 82.76, 152.76, 172.08, 176.34.
FAB-MS 489 (M+H)+.
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(B o c )2N

HATU, DIEA

/

\
4.7

4.6

4.3.6

3-(R H V ',A T-[l,l-dunethylethoxy)carboiiyl]-am ino~l>[l>(S)m ethylelhylethanoic acid]-2-piperidinone (4.7)
Compound 4.6 (1.05 g, 2.15 mmol) was dissolved in dry CH3CN (15 mL) and

kept under argon. HATU (0.82 g, 2.15 mmol, 1 equiv.) was added, followed by DIEA
(0.79 mL, 4.52 mmol, 2.1 equiv.). The solution was stirred for 2 hours after which the
solvent was removed under reduced pressure. The residue was taken up in hexanes:ethyl
acetate (3:1) and purified by flash column chromatography to give 4.7 as a white solid
(0.78 g, 77%). ‘H NMR (250 MHz, CDC13) 8 0.98 (m, 6 H), 1.44 (s, 9H), 1.49 (s, I 8 H),
1.69 (m, 1H), 1.84 (m, 2H), 2.15 (m, 2H), 3.28 (m, 1H), 3.56 (m, 1H), 4.78 (m, 1H),
4.92 (d, 1H). 13C NMR (62.5 MHz, CDC13) 8 19.49, 19.96, 22.84, 27.10, 27.94, 28.31,
43.85, 57.06, 61.99, 81.42, 82.71, 152.97, 168.45, 170.73.

FAB-MS 472 (M+H)+.

Anal, calcd for C24H42N20 7: C, 61.24; H, 9.00; N, 5.95. Found: C, 61.03; H, 8.65; N,
6 .02 .
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1) TFA/DCM (1:1)
2) Na2C 0 3
O tB o

(Boc^f*

F m o cfJ

3) Fmoc-OSu, Dioxane

OH

1

H

4.7

4.3.7

3-(R)-jV '-[(9H-fluoren-9-ylmethoxy)carbonyl]-ainino-l-[l-(S)methylethylethanoic acid]-2-piperidinone
Compound 4.7 (1.32 g, 2.80 mmol) was treated with TFA/DCM (1:1,5 mL) and

stirred for 15 minutes. The solvent was evaporated and the resulting yellow oil was taken
up in sufficient 9% Na2C 0 3 to give a solution with pH 9. The solution was cooled in an
ice bath and a solution of Fmoc-OSu (0.99 g, 2.94 mmol. 1.05 equiv.) in dioxane (10
mL) was added. The solution was allowed to stir at room temperature for 2 hours after
which the reaction mixture was diluted with water (100 mL). The reaction mixture was
extracted with ether (1 x 50 mL) then with ethyl acetate (2 x 50 mL). The aqueous phase
was cooled to 0° C, acidified to pH 2 with concentrated hydrochloric acid and then
extracted with ethyl acetate (4 x 50 mL). The organic layer was dried over Na2S 0 4 and
evaporated. The remaining clear oil is taken up in 1% acetic acid in CHCls/MeOH (9:1)
and purified by flash column chromatography. The solvent was evaporated to yield 4.8
as an off white solid (0.62 g, 51%). lH NMR (250 MHz, CDC13) 50.96 (d, 3H), 1.09 (d,
3H), 1.28 (m, 1H), 2.07 (m, 2H), 2.45 (m, 2H), 3.47 (m, 2H), 4.26 (m, 3H), 4.41 (d,
1H), 5.86 (m, 1H), 7.52 (m, 8 H). ,3C NMR (62.5 MHz, CDC13) 5 19.17, 19.99, 20.49,
26.61, 27.15, 45.08, 47.09, 51.79, 64.78, 67.08, 119.89, 125.16, 127.05, 127.65, 141.26,
143.81, 143.91, 156.34, 171.38, 173.43. FAB-MS 437 (M +H)+.
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1) TFA/DCM (1:1)
OtBu

(B o c )2N

2) TMS-C1, DIEA.
Fmoc-Cl

OH

Pmocr*

4.7

4.8

Alternative procedure for 4.8. Compound 4.7 (1.72 g, 3.65 mmol) was treated
with TFA/DCM (1:1,5 mL) and stirred for 15 minutes. The solvent was evaporated and
the resulting yellow oil was dissolved in dry DCM (30 mL). DIEA (1.97 mL, 11.3
mmol, 3.1 equiv.) was added and the solution cooled to 0° C. TMS-C1 (0.92 mL, 7.28
mmol, 2.0 equiv.) was added and the solution stirred for 2 hours. The solution was again
cooled to 0° C and Fmoc-Cl (0.94 g, 3.64 mmol, 1.0 equiv.) dissolved in dry DCM (10
mL) was added. The reaction was stirred for 4 hours at room temperature after which
the DCM was evaporated. The residue was taken up in 2.5% Na 2C 0 3 (25 mL) and
washed with ether (2 x 50 mL). The aqueous layer was cooled to 0° C and acidified to
pH 2 using concentrated hydrochloric acid. The precipitated product is extracted with
ethyl acetate (4 x 50 mL). The organic layer is dried over Na2S 0 4 and the solvent
removed to yield a clear oil.

The crude product is taken up in 1% acetic acid in

CHCl3/MeOH (9:1) and purified by flash column chromatography. The solvent was
evaporated to yield 4.8 as an off white solid (1.37 g, 85%).
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4.3.8

Peptide Synthesis
The peptide under study was synthesized via solid-phase peptide synthesis using

a Milligen 9050 peptide synthesizer on PAL-PEG-PS solid support. Four equivalents of
each amino acid, 3 equivalents of DIEA, 4 equivalents of HATU and a one-hour
recycling time were used for the couplings.

A solution of 20% piperidine/2% 1,8-

diazobicyclo[4.5.0]undec-7-ene (DBU) in DMF was used for Fmoc removal.

The

peptide was acetylated on the solid support by treatment with a 0.2M solution o f acetic
anhydride in 0.28M DIEA in DMF for 40 minutes. The peptide was simultaneously
cleaved

from

the

resin and

side-chain

deprotected

triisopropylsilane, water, phenol (8.8:0.2:0.5:0.5).

4 30

using reagent

B,

TFA,

The resulting acidic solution was

diluted with 30% acetic acid, washed with ether (4 x 50 mL) and lyophilized. The crude
peptide was purified by preparative reverse-phase HPLC on a Waters 15 pM Deltapak
C 4 column using a water (0.05% TFA) and acetonitrile (0.05% TFA) gradient system.
The gradient was run from 10% to 70% organic and the absorption monitored at 222 nm.
Purity of the peptide was checked on a Vydac 5 pM Q 8 column using the same
conditions. Matrix assisted laser desorption ionization (MALDI) mass spectrometry was
used to verify peptide mass, 1093 (M+H)+.
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C hapter 5
Sum m ary and F uture Studies
5.1 Sum m ary and F u tu re Studies
This dissertation focused on the synthesis and studies of helical peptides and the
synthesis of an amino acid designed to nucleate P-sheet dimer formation. The short,
helical peptides were rich in a , a-disubstituted amino acids (a a A A ’s) and designed to
be amphipathic.

Helix preferences of the peptides in several solvent systems were

studied as was antimicrobial activity.

A peptide utilizing the constrained lactam

dipeptide amino acid was synthesized and studied for p-sheet dimer formation.
Chapter 2 outlined the synthesis of short, amphipathic helical peptides. The helix
type and percent helicity of the peptides was determined using circular dichroism
spectroscopy.

In addition, in vivo and in vitro studies were done to determine the

effectiveness of the peptides in eliminating intracellular pathogens. The peptides were
synthesized to determine if short, amphipathic peptides would exhibit increased
biological activity against bacteria versus mammalian cells.

It has been shown that

shorter peptides are more selective and more helical peptides are more active.

5 1-5 4

To increase the helicity of the peptides, a aA A ’s were used .5 '5 5-7 Pre-formed acid
fluorides of a-aminoisobutyric acid (Aib), 1-aminocyclohexanecarboxylic acid (Cyh)
5 8-5 9

and 4-aminopiperidine-4-carboxylic acid (Api) were used in the synthesis. '

The

use of Api allowed a polar aaA A to be used on the polar face of the amphipathic
peptides. Once synthesized, the peptides were tested in vitro for direct antimicrobial
activity against E. coli and S. aureus. All of the peptides showed good activity against E.
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coli while the more hydrophobic peptides, Cyh-10 and Ich-10 had excellent activity
against S. aureus. Several of the peptides were tested against macrophages infected with
intracellular pathogens.

In vivo and in vitro studies were done to evaluate the

effectiveness of several peptides in eliminating these pathogens. B. abortus and M.
chelonei were used as representative intracellular pathogens.

P i-10 and Ich-10

significantly reduced the B. abortus load in BALB/c mice. Pi-10 showed a 90% B.
abortus reduction with a single dose o f 500 pg whereas Ich-10 showed an 82% B.
abortus reduction with a single dose of 25 pg.
Brucella abortus expressing a green fluorescent protein and Mycobacterium
chelonei were used to test if Pi-10 is selective in destroying only infected macrophages.
Using these bacteria, infected macrophages can be visualized easily.

Trypan blue

exclusion identifies dead macrophages. Test results were promising. Further studies
need to be done to improve control over the number of macrophages infected.

In

addition, fluorescently labeled peptides should be synthesized to determine the binding
affinity of the peptides for infected versus non-infected macrophages.
Chapter 3 outlines the solvent effects on the helix preferences of a series of
amphipathic peptides.

P i-10 and Cyh-10 were designed to be amphipathic a-helical

peptides while Ipi-10 and Ich-10 were designed to be amphipathic 310-helical peptides.
All peptides contained 80% aaA A ’s.
According to the literature, P i-10 and Cyh-10 should display CD spectra typical
for a 3 ,0-helix in SDS micelles due to their high aaA A content and the position of the
proteinogenic amino acids.5'5’ 5 1 0

Instead, both peptides formed an a-helix in SDS

micelles, demonstrating the importance o f amphipathy in determining helix preference.
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Ipi-10, a sequence permutation isomer of P i-10, showed the expected 3t0-helix spectrum.
Ich-10, a sequence permutation isomer of Cyh-10, did not display a 3I0-helix spectrum as
anticipated. Instead, a spectrum indicative of an a-helix was observed. It is theorized
that the side-chains of the cyclohexyl amino acid residues are sterically congested in a
3 ,0-helix,

forcing the peptide to adopt an a-helix conformation.

Various organic and aqueous/organic solvent systems were studied to determine
the effects on helix preferences.
solvent systems.

Pi-10 and Cyh-10 displayed a-helix spectra in all

As expected, Ipi-10 adopted a 3,0-helix structure in 100% organic

solvent but shifted to an a-helix as the water content increases. As in SDS micelles, Ich10 adopted an a-helix conformation in all solvent systems tested. The demonstration
that amphipathy, rather than aaA A content, controls helix preference can be further
investigated by altering the sequence of Ich-10 to reduce the steric hinderance of the
side-chains.
Chapter

4

described

the

synthesis

of

yImethoxy)carbonyl]-amino-1-[ 1-(S)-methylethylethanoic

3-(R)-N -[(9H-fluoren-9acid]-2-piperidinone,

a

constrained lactam dipeptide amino acid. The amino acid was synthesized to incorporate
into peptides designed to form intermolecular p-sheet dimers.

The amino acid was

synthesized beginning with the complete allyl esterification and double nitrogen
protection of D-glutamic acid. The key step in the sequence is the selective DEBAL
reduction of the side-chain allyl ester to the aldehyde .5 ' 11 A reductive amination with Lvaline-OtBu is carried out followed by removal of the remaining allyl ester. Cyclization
of the amino acid followed by removal of the a-nitrogen protecting groups and ferf-butyl

133

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

ester on the valine moiety yielded the free constrained lactam dipeptide amino acid.
Protection of the a-nitrogen with the Fmoc group gives the target amino acid ready for
peptide synthesis.
The target amino acid was incorporated into a peptide pre-designed to form a 13sheet dimer. The structure of the peptide was studied in various solvents, pH levels and
concentrations. Unfortunately, only random coil spectra were observed. It is possible
that the minimum number of constrained lactam dipeptide amino acids has not been
reached. Future studies should concentrate on synthesizing a series of peptides, each
with increasing numbers of constrained lactam dipeptide amino acid residues. These
peptides can then be studied to determine the minimum number of constrained lactam
dipeptide amino acid residues needed to nucleate p-sheet dimer formation. It would also
prove helpful to synthesize a peptide containing a (3-tum. D-proline-glycine is a known
5 12 5 13

P-tum. ’ ’

Using this P-tum would result in an intramolecular P-sheet dimer,

rather than intermolecular, but it would aid greatly in the characterization of a p-sheet
dimer.
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